var title_f37_8_38016="Cavernous malformation MRI";
var content_f37_8_38016=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F80348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F80348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRI of a cerebral cavernous malformation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 271px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cavernous malformations appear characteristically on MRI as a \"popcorn\" pattern of variable image intensities.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Guy Rordorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_8_38016=[""].join("\n");
var outline_f37_8_38016=null;
var title_f37_8_38017="Angiogram RCVS";
var content_f37_8_38017=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F66139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F66139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Cerebral angiography of a patient with reversible cerebral vasoconstriction syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the multiple areas of stenosis (white arrow) and dilatation (red arrow) in multiple vessels of the M2 branch of the middle cerebral artery (A) and their resolution after&nbsp;one month (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hajj-Ali RA, Furlan A, Abou-Chebel A, Calabrese LH. Benign angiopathy of the central nervous system: cohort of 16 patients with clinical course and long-term followup. Arthritis Rheum 2002; 47:662. Copyright &copy; 2002 John Wiley &amp; Sons, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_8_38017=[""].join("\n");
var outline_f37_8_38017=null;
var title_f37_8_38018="Contents: Neonatology";
var content_f37_8_38018=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?6/40/6798\">",
"       Obstetrics, Gynecology and Women's Health",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Neonatology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Neonatology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Antenatal drug exposure",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/4/28746\">",
"           Infants of mothers with substance abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/29/11736\">",
"           Infants with antenatal exposure to serotonin reuptake inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/57/39833\">",
"           Neonatal opioid withdrawal (Neonatal abstinence syndrome)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cardiac disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/56/20359\">",
"           Cardiac causes of cyanosis in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/2/43048\">",
"           Diagnosis and initial management of cyanotic heart disease in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/62/1002\">",
"           Management of patent ductus arteriosus in premature infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/57/24474\">",
"           Neonatal lupus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/50/15145\">",
"           Pathophysiology, clinical manifestations, and diagnosis of patent ductus arteriosus in premature infants",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Congenital anomalies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/62/11237\">",
"           Anencephaly",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/18/8487\">",
"           Craniosynostosis syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/34/44581\">",
"           Facial clefts and holoprosencephaly",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/13/7386\">",
"           Genetic and environmental causes of birth defects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/21/6488\">",
"           Obstetrical and neonatal management of body stalk anomalies and cloacal abnormalities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/35/38454\">",
"           Obstetrical management of omphalocele",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/37/10841\">",
"           Overview of craniosynostosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/62/33767\">",
"           Pathophysiology and clinical manifestations of myelomeningocele (spina bifida)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/57/3991\">",
"           Primary (congenital) encephalocele",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/15/250\">",
"           Syndromes with craniofacial abnormalities",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Congenital malformations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/62/11237\">",
"           Anencephaly",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/29/7639\">",
"           Lower extremity positional deformations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/62/33767\">",
"           Pathophysiology and clinical manifestations of myelomeningocele (spina bifida)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/57/3991\">",
"           Primary (congenital) encephalocele",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Dermatologic disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/13/22745\">",
"           Benign skin and scalp lesions in the newborn and young infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/43/6840\">",
"           Skin nodules in newborns and infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/21/30038\">",
"           Vascular lesions in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/31/15864\">",
"           Vesiculobullous and pustular lesions in the newborn",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Endocrine disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/39/2682\">",
"           Clinical features and detection of congenital hypothyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/6/97\">",
"           Evaluation and management of neonatal Graves' disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/59/24506\">",
"           Evaluation of the infant with ambiguous genitalia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/48/44809\">",
"           Infant of a diabetic mother",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/47/35577\">",
"           Management of the infant with ambiguous genitalia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/59/37816\">",
"           Neonatal hyperglycemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/23/26999\">",
"           Neonatal hypocalcemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/16/17673\">",
"           Neonatal hypoglycemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/47/40696\">",
"           Thyroid physiology and screening in preterm infants",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gastrointestinal disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/39/41591\">",
"           Clinical features and diagnosis of necrotizing enterocolitis in newborns",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/8/34950\">",
"           Emergency complications of Hirschsprung disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/6/23657\">",
"           Gastroesophageal reflux in premature infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/55/31608\">",
"           Intestinal atresia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/5/35928\">",
"           Management of necrotizing enterocolitis in newborns",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/15/41205\">",
"           Overview of the development of the gastrointestinal tract",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/28/28105\">",
"           Pathology and pathogenesis of necrotizing enterocolitis in newborns",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/2/7207\">",
"           Prevention of necrotizing enterocolitis in newborns",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/31/32247\">",
"           Spontaneous intestinal perforation of the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/4/21576\">",
"           Sucking and swallowing disorders in the newborn",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hematologic disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/19/20792\">",
"           Anemia of prematurity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/54/42856\">",
"           Diagnosis of sickle cell syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/52/3912\">",
"           Hemolytic disease of the newborn: RBC alloantibodies in pregnancy and associated serologic issues",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/40/14986\">",
"           Management of thrombosis in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/6/36968\">",
"           Neonatal polycythemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/9/14490\">",
"           Neonatal thrombocytopenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/16/14600\">",
"           Pathogenesis, clinical features, and diagnosis of thrombosis in the newborn",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hyperbilirubinemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/60/24519\">",
"           Approach to neonatal cholestasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/18/27943\">",
"           Bilirubin metabolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/50/16169\">",
"           Causes of neonatal cholestasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/63/25593\">",
"           Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/39/11898\">",
"           Evaluation of unconjugated hyperbilirubinemia in term and late preterm infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/60/19400\">",
"           Hyperbilirubinemia in the premature infant (less than 35 weeks gestation)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/3/39992\">",
"           Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/45/16083\">",
"           Patient information: Jaundice in newborn infants (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/59/21434\">",
"           Treatment of unconjugated hyperbilirubinemia in term and late preterm infants",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Inborn errors of metabolism",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/26/27047\">",
"           Inborn errors of metabolism: Classification",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/58/24489\">",
"           Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/55/13177\">",
"           Inborn errors of metabolism: Identifying the specific disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/0/10250\">",
"           Inborn errors of metabolism: Metabolic emergencies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/16/17673\">",
"           Neonatal hypoglycemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/30/24037\">",
"           Antiretroviral medications in pregnancy: Entry and integrase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/60/16328\">",
"           Antiretroviral medications in pregnancy: Non-nucleoside reverse transcriptase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/53/42841\">",
"           Antiretroviral medications in pregnancy: Nucleoside reverse transcriptase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/24/18825\">",
"           Antiretroviral medications in pregnancy: Protease inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/21/27992\">",
"           Chlamydia trachomatis infections in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/47/7928\">",
"           Clinical features and diagnosis of bacterial meningitis in the neonate",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/16/6410\">",
"           Clinical features and diagnosis of sepsis in term and late preterm infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/62/31720\">",
"           Clinical manifestations and diagnosis of Candida infection in neonates",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/49/10010\">",
"           Congenital rubella syndrome: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/63/36855\">",
"           Congenital rubella syndrome: Management, outcome, and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/17/28951\">",
"           Definition and etiology of fever in neonates and infants (less than three months of age)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/30/24039\">",
"           Epidemiology and risk factors for Candida infection in neonates",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/0/31749\">",
"           Epidemiology of pediatric HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/26/28074\">",
"           Evaluation and management of fever in the neonate and young infant (less than three months of age)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/34/39462\">",
"           Gonococcal infection in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/16/18698\">",
"           Group B streptococcal infection in neonates and young infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/63/37881\">",
"           Hepatitis viruses and the newborn: Clinical manifestations and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/3/3130\">",
"           Natural history and classification of pediatric HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/31/35321\">",
"           Neonatal herpes simplex virus infection: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/48/40713\">",
"           Neonatal herpes simplex virus infection: Management and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/0/21512\">",
"           Neonatal pneumonia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/4/13384\">",
"           Non-antiretroviral interventions to reduce perinatal HIV transmission in the developing world",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/43/10936\">",
"           Nosocomial viral infections in the neonate",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/24/28041\">",
"           Overview of TORCH infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/29/40408\">",
"           Parvovirus B19 infection during pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/48/9991\">",
"           Prevention of Candida infection in neonates",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/38/40550\">",
"           Strategies for the evaluation of fever in neonates and infants (less than three months of age)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/47/16121\">",
"           Treatment and outcome of bacterial meningitis in the neonate",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/37/26200\">",
"           Treatment and outcome of sepsis in term and late preterm infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/51/40760\">",
"           Treatment of Candida infection in neonates",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/12/29896\">",
"           Unusual fungal infections in the neonate",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/59/14264\">",
"           Urinary tract infections in newborns",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/11/4278\">",
"           Varicella-zoster infection in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/19/26936\">",
"           Vertical transmission of hepatitis C virus",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neonatal assessment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/7/31863\">",
"           Assessment of neonatal pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/21/24922\">",
"           Assessment of the newborn infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/30/27113\">",
"           Clinical features and diagnosis of developmental dysplasia of the hip",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/11/14520\">",
"           Incidence and mortality of the premature infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/4/28746\">",
"           Infants of mothers with substance abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/21/20823\">",
"           Large for gestational age newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/11/22713\">",
"           Late preterm infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/1/27672\">",
"           Limit of viability",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/31/13814\">",
"           Long-term complications of the premature infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/6/34922\">",
"           Long-term neurodevelopmental outcome of premature infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/23/35188\">",
"           Metabolic emergencies at birth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/60/27594\">",
"           Neonatal outcome, complications, and management of multiple births",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/10/14505\">",
"           Neurological examination of the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/23/10616\">",
"           Overview of causes of and risk factors for fetal growth restriction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/38/21096\">",
"           Perinatal mortality",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/19/8502\">",
"           Physiologic transition from intrauterine to extrauterine life",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/35/22068\">",
"           Postnatal assessment of gestational age",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/26/31142\">",
"           Postterm infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/57/5016\">",
"           Primary infantile glaucoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/15/31992\">",
"           Short-term complications of the premature infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/23/9593\">",
"           Small for gestational age infant",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neonatal care",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/29/11738\">",
"           Care of the neonatal intensive care unit graduate",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/47/41721\">",
"           Care of the umbilicus and management of umbilical disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/7/27765\">",
"           Discharge planning for high-risk newborns",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/2/39975\">",
"           Etiology, clinical manifestations, and evaluation of neonatal shock",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/60/27591\">",
"           Fluid and electrolyte therapy in newborns",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/22/23912\">",
"           Growth management in preterm infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/47/22265\">",
"           Neonatal birth injuries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/57/39833\">",
"           Neonatal opioid withdrawal (Neonatal abstinence syndrome)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/16/36105\">",
"           Overview of the routine management of the healthy newborn infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/9/10393\">",
"           Postnatal care of hydrops fetalis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/18/35114\">",
"           Prevention and treatment of neonatal pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/53/9048\">",
"           Red blood cell transfusions in the newborn",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neonatal procedures",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/46/41705\">",
"           Neonatal circumcision: Risks and benefits",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/57/15256\">",
"           Techniques for neonatal circumcision",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neonatal resuscitation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/46/26346\">",
"           Neonatal resuscitation in the delivery room",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/6/17513\">",
"           Overview of cyanosis in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/61/29656\">",
"           Oxygen monitoring and therapy in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/59/29623\">",
"           Systemic effects of perinatal asphyxia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neonatal screening",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/2/2088\">",
"           Newborn screening",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/13/27865\">",
"           Screening the newborn for hearing loss",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neurologic disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/13/34004\">",
"           Approach to the infant with hypotonia and weakness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/11/6328\">",
"           Clinical features and electrodiagnosis of neonatal seizures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/33/29209\">",
"           Clinical features of cerebral palsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/24/2442\">",
"           Clinical features, diagnosis, and treatment of neonatal encephalopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/44/42697\">",
"           Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/6/13417\">",
"           Congenital myopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/0/4104\">",
"           Diagnosis and classification of cerebral palsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/50/41768\">",
"           Epidemiology and etiology of cerebral palsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/15/1273\">",
"           Etiology and pathogenesis of infantile spasms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/14/30953\">",
"           Etiology and pathogenesis of neonatal encephalopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/23/41335\">",
"           Etiology and prognosis of neonatal seizures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/54/5994\">",
"           Hydrocephalus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/46/31465\">",
"           Management and complications of intraventricular hemorrhage in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/37/15962\">",
"           Management and prognosis of cerebral palsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/60/35783\">",
"           Neonatal epileptic syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/10/166\">",
"           Neuromuscular junction disorders in newborns and infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/48/11015\">",
"           Overview of peripheral nerve and muscle disorders causing hypotonia in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/7/33913\">",
"           Periventricular leukomalacia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/2/27690\">",
"           Stroke in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/0/13\">",
"           Treatment of neonatal seizures",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nutrition",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/8/19593\">",
"           Approach to enteral nutrition in the premature infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/21/13657\">",
"           Breast milk expression for the preterm infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/12/36040\">",
"           Breastfeeding the preterm infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/39/42616\">",
"           Breastfeeding: Parental education and support",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/39/40567\">",
"           Calcium and phosphorus requirements of newborn infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/15/17658\">",
"           Common problems of breastfeeding and weaning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/6/23655\">",
"           Human milk feeding and fortification of human milk for premature infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/47/32505\">",
"           Infant benefits of breastfeeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/1/8217\">",
"           Initiation of breastfeeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/27/1461\">",
"           Maternal and economic benefits of breastfeeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/53/43864\">",
"           Maternal nutrition during lactation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/28/458\">",
"           Nutritional composition of human milk and preterm formula for the premature infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/36/6727\">",
"           Nutritional composition of human milk for full-term infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/50/27434\">",
"           Parenteral nutrition in premature infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/23/6519\">",
"           Physiology of lactation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/1/32794\">",
"           Principles of medication use during lactation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/61/39896\">",
"           n-3 Long chain polyunsaturated fatty acids (LCPUFA) for preterm and term infants",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ophthalmologic disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/32/10762\">",
"           Retinopathy of prematurity",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Renal and urological disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/30/27114\">",
"           Acute kidney injury (acute renal failure) in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/24/24966\">",
"           Clinical manifestations and initial management of infants with bladder exstrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/36/7753\">",
"           Congenital and infantile nephrotic syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/60/37833\">",
"           Etiology, clinical features, and diagnosis of neonatal hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/59/42936\">",
"           Management of hypertension in infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/47/26356\">",
"           Nephrocalcinosis in neonates",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/52/42824\">",
"           Overview of antenatal hydronephrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/20/34119\">",
"           Postnatal management of antenatal hydronephrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/58/16296\">",
"           Prenatal diagnosis of renal agenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/23/44407\">",
"           Prune-belly syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Respiratory disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/29/29144\">",
"           Bronchopulmonary sequestration",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/16/21768\">",
"           Clinical features and diagnosis of meconium aspiration syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/23/28026\">",
"           Congenital diaphragmatic hernia in the neonate",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/11/44214\">",
"           Congenital lobar emphysema",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/50/810\">",
"           Congenital pulmonary airway (cystic adenomatoid) malformation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/5/36951\">",
"           Diaphragmatic paralysis in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/14/43235\">",
"           Eventration of the diaphragm in infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/13/43223\">",
"           Management of apnea of prematurity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/24/15753\">",
"           Management of bronchopulmonary dysplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/39/4729\">",
"           Mechanical ventilation in neonates",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/51/25398\">",
"           Outcome of infants with bronchopulmonary dysplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/49/31511\">",
"           Overview of neonatal respiratory distress: Disorders of transition",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/22/18793\">",
"           Pathogenesis and clinical features of bronchopulmonary dysplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/4/12360\">",
"           Pathogenesis, clinical presentation, and diagnosis of apnea of prematurity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/12/19656\">",
"           Pathophysiology and clinical manifestations of respiratory distress syndrome in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/37/27225\">",
"           Persistent pulmonary hypertension of the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/17/3353\">",
"           Postnatal use of glucocorticoids in bronchopulmonary dysplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/13/18648\">",
"           Prevention and management of meconium aspiration syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/34/43561\">",
"           Prevention and treatment of respiratory distress syndrome in preterm infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/14/27880\">",
"           Prevention of bronchopulmonary dysplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/33/4631\">",
"           Pulmonary air leak in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/40/17034\">",
"           Pulmonary outcomes of bronchopulmonary dysplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/2/32804\">",
"           Transient tachypnea of the newborn",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Systemic disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/57/24474\">",
"           Neonatal lupus",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-33CC5CE337-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f37_8_38018=[""].join("\n");
var outline_f37_8_38018=null;
var title_f37_8_38019="Tetracaine (systemic): Patient drug information";
var content_f37_8_38019=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tetracaine (systemic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24148?source=see_link\">",
"     see \"Tetracaine (systemic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/8/43138?source=see_link\">",
"     see \"Tetracaine (systemic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9564871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pontocaine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691415",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to numb an area of the skin before care.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703010",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tetracaine, aminobenzoic acid, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696752",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not eat while your mouth feels numb. You may bite your tongue.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698288",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness and tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any pain during care.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad numbness and tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will give this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12316 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.80.101-F119FB24C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_8_38019=[""].join("\n");
var outline_f37_8_38019=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564871\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025845\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025844\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025849\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025850\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025852\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025847\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025854\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/45/27347?source=related_link\">",
"      Tetracaine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/36/17987?source=related_link\">",
"      Tetracaine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/18/13603?source=related_link\">",
"      Tetracaine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24148?source=related_link\">",
"      Tetracaine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/8/43138?source=related_link\">",
"      Tetracaine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?28/30/29155?source=related_link\">",
"      Tetracaine (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/3/25652?source=related_link\">",
"      Tetracaine (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/31/2547?source=related_link\">",
"      Tetracaine (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_8_38020="Fondaparinux: Patient drug information";
var content_f37_8_38020=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fondaparinux: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     see \"Fondaparinux: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F174015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Arixtra&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F174016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Arixtra&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700437",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       People who have had recent spinal anesthesia, epidurals, or spinal taps are more likely to have bleeding problems when started on this drug. This bleeding rarely happens, but can be very bad. Tell your doctor if you have had any spinal care. Do not take any other blood-thinner drugs including nonsteroidal anti-inflammatory drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705929",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor you use this drug before you get spinal anesthesia or a spinal treatment.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to thin the blood so that clots will not form.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to fondaparinux or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a latex allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you weigh less than 110 pounds (50 kilograms).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703365",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bleeding, a heart infection called endocarditis, or poor kidney function.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bleeding problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697879",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698276",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698081",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698653",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fall or crash when you hit your head. Talk with your doctor even if you feel fine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12496 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-5846377118-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_8_38020=[""].join("\n");
var outline_f37_8_38020=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174015\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174016\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028801\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028803\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028802\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028807\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028808\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028810\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028805\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028806\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028811\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028812\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=related_link\">",
"      Fondaparinux: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_8_38021="Epidemiology of herpes simplex virus type 1 infection";
var content_f37_8_38021=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology of herpes simplex virus type 1 infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/8/38021/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/8/38021/contributors\">",
"     Robyn S Klein, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/8/38021/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/8/38021/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/8/38021/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/8/38021/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/8/38021/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herpes simplex virus type 1 (HSV-1) infections are frequently asymptomatic but can produce a variety of signs and symptoms. These include oral or perioral lesions, ocular infections, nongenital skin lesions, genital skin or mucous membrane lesions, and serious systemic illnesses such as encephalitis and neonatal disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=see_link\">",
"     \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HSV-1 is transmitted from person-to-person via infected oral secretions during close contact. Infection occurs worldwide, equally between the sexes, and without seasonal variation. In the United States, there are estimated to be approximately 500,000 primary infections per annum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/1\">",
"     1",
"    </a>",
"    ]. The incubation period of oral infections ranges from 1 to 26 days (median 6 to 8 days) and lesions range from 1 to 8 days in duration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. While infection is lifelong, it is rarely fatal in the immunocompetent host, producing either asymptomatic or mild clinical disease.",
"   </p>",
"   <p>",
"    Herpetic keratitis continues to be the leading cause of blindness in industrialized countries, with the predominant disease being of the stromal type [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/4\">",
"     4",
"    </a>",
"    ]. Over the past 20 years, the prevalence of the disease has decreased in most developed countries. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/12/33992?source=see_link\">",
"     \"Herpes simplex keratitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contact with herpetic lesions or oral secretions can produce infection with HSV-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/2\">",
"     2",
"    </a>",
"    ]. The viral titer is 100 to 1000 times greater when lesions are present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/3\">",
"     3",
"    </a>",
"    ]; as a result, transmission is much more likely when the patient is symptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/2\">",
"     2",
"    </a>",
"    ]. Following primary infection, HSV can also sometimes be recovered from the stool [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In various series, HSV was obtained from 81 to 88 percent of vesicles, 34 percent of ulcers or crusts, and from the saliva in 3.6 to 25 percent of patients with a positive history or serology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/2,6,7\">",
"     2,6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, 2 to 9 percent of adults and 5 to 8 percent of children were asymptomatic salivary excretors of HSV-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/3\">",
"     3",
"    </a>",
"    ]. Overall, 0.65 to 15 percent of adults may be excreting HSV-1 (or HSV-2) at anytime. There does not appear to be a correlation between ocular and oral infection with HSV-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transmission of ocular HSV-1 has also been documented in a case of corneal transplantation into a HSV-1 seronegative patient with glaucoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/9\">",
"     9",
"    </a>",
"    ]. This infection resulted in the loss of sight.",
"   </p>",
"   <p>",
"    HSV-1 transmission via oral-genital contact has also been recognized as a contributing cause of increasing cases of HSV-1 genital herpes infection, especially among young adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SEROEPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Worldwide, more than 90 percent of people are seropositive for HSV-1 by the fourth decade of life, especially those of lower socioeconomic groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/3\">",
"     3",
"    </a>",
"    ]. This pattern was also present in the United States during the 1940s and 1950s; however, the prevalence rates for people from industrialized countries and middle class societies have been declining. In a follow-up cross-sectional seroprevalence survey in the United States, trends in HSV-1 and HSV-2 infections in 1999 to 2004 (11,508 participants) were compared to 1988 to 1994 (9165 participants) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/12\">",
"     12",
"    </a>",
"    ]. The survey demonstrated that the seroprevalence of HSV-1 had declined from 62 to 58 percent, a relative decrease of seven percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/12\">",
"     12",
"    </a>",
"    ]. A European study determined a seroprevalence of 65.6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/13\">",
"     13",
"    </a>",
"    ]. Subsequent data indicate that seroprevalence for both HSV-1 and HSV-2 in the United States is decreasing, suggesting that young adults may be at increased risk for primary infections with these viruses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is unclear whether the declining rate is secondary to changes in hygiene or to a protective effect of infection with HSV-2, the prevalence of which has been rising in developed societies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/3\">",
"     3",
"    </a>",
"    ]. In one prospective study of new HSV-1 and HSV-2 infections, approximately two-thirds of new HSV-1 infections were symptomatic and genital infections due to HSV-1 were as common as oropharyngeal infections (0.5 cases per 100 person-years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/15\">",
"     15",
"    </a>",
"    ]. Two studies have demonstrated that prior seropositivity to HSV-1 increased the likelihood of asymptomatic seroconversion for HSV-2 infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/13,15\">",
"     13,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, seroprevalence has been reexamined using newer type-specific antibody assays and sera from the National Health and Nutrition Examination Survey [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/16\">",
"     16",
"    </a>",
"    ]. Among African-American children, more than 35 percent were positive for HSV-1 by the age of five compared to 18 percent in Caucasian children. HSV-1 antibodies remained two times more common in African-Americans through adolescence but the difference had disappeared by age 40.",
"   </p>",
"   <p>",
"    For patients with a positive history of cold sores, the rates of seropositivity are higher (93 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/17\">",
"     17",
"    </a>",
"    ]. Antibody titers have not been found to correlate with positive cultures or the presence of lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Populations at risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous and ocular HSV-1 infections have been recognized as a health risk for athletes involved in contact sports and for healthcare workers. One study, for example, evaluated students at a high school wrestling camp: 34 percent had active herpetic infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/18\">",
"     18",
"    </a>",
"    ], which commonly involved the head (73 percent), extremities (42 percent), and trunk (28 percent). Interestingly, attack rates for wrestlers were higher for heavyweights compared to lightweights (67 versus 25 percent).",
"   </p>",
"   <p>",
"    Healthcare workers comprise a second population at risk for infection with HSV-1. One report found that medical and nursing personnel had a slightly lower prevalence of antibodies to HSV-1 (less than 50 percent) than the general population (80 to 90 percent), making them particularly susceptible to primary infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, HSV-1 is responsible for nosocomial outbreaks in many hospitals, providing another reason to adopt universal precautions.",
"   </p>",
"   <p>",
"    In one reported case, a physician developed HSV-1 keratoconjunctivitis after intubating an immunocompromised patient with pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/20\">",
"     20",
"    </a>",
"    ]. The physician had not been wearing eye protection or gloves during the procedure. In that hospital, nosocomial HSV-1 infection occurred in 9 to 15 of 10,000 hospital admissions per year.",
"   </p>",
"   <p>",
"    Restriction endonuclease fingerprinting of HSV DNA has been used for contact tracing in nosocomial outbreaks of HSV. In at least one instance, it revealed that multiple isolates occurred in a \"single\" outbreak [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There may also be groups at reduced risk. There are, for example, two studies suggesting possible protection afforded by prior infection with one serotype of HSV on infection with the other. In one report, pregnant women with no prior infection with HSV had a 3.7 percent chance of seroconverting to HSV-2 during their pregnancy compared to 1.7 percent in those with prior exposure to HSV-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/22\">",
"     22",
"    </a>",
"    ]. In another study of Japanese women with genital herpes, isolation of HSV-1 from the lesions correlated with seronegativity for HSV-2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transmission of neonatal HSV-1 generally occurs from nongenital and occasionally nonmaternal sources. In one series of six infants diagnosed with HSV-1 infection, only four mothers had past or current mucocutaneous HSV-1 infection, while all six fathers had positive histories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/24\">",
"     24",
"    </a>",
"    ]. In one set, neither parent had active HSV at the time of neonatal infection.",
"   </p>",
"   <p>",
"    A rapid rise in HSV-1 antibodies occurs during the first five years of life, coincident with a rise in primary infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/19\">",
"     19",
"    </a>",
"    ]. In one report, 20 percent of normal children between the ages of seven months and two years had HSV in their saliva [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     HSV-1 RECURRENCE PATTERNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent HSV-1 infections of the lips and perioral area are estimated to occur in 20 to 40 percent of the population worldwide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/6\">",
"     6",
"    </a>",
"    ]. Among patients with recurrence, there is substantial variability in the frequency with which this occurs, ranging from once per month in 5 to 23 percent to every one to four months in 58 to 61 percent to twice per year in 19 to 61 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/6,25\">",
"     6,25",
"    </a>",
"    ]. No differences between the sexes have been observed.",
"   </p>",
"   <p>",
"    Recurrent ocular HSV-1 infections are also common. Approximately 25 to 50 percent of patients with primary herpetic keratitis will have a recurrence within two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HSV-1 recurs more often in the orolabial region and HSV-2 recurs more often in the genital area [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/1,27\">",
"     1,27",
"    </a>",
"    ]. In one study, for example, the mean monthly recurrence rate for orolabial HSV-1 was twenty-fold higher than for orolabial HSV-2 (0.020 versus 0.001) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/27\">",
"     27",
"    </a>",
"    ]. In the same report, the rate of genital HSV-2 recurrences was much higher (0.33 per month).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     THE IMMUNOCOMPROMISED HOST",
"    </span>",
"    &nbsp;&mdash;&nbsp;HSV-1 infection in the immunocompromised host causes more morbidity and mortality than in the general population. This relationship can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series, 62 percent of fatalities following renal transplantation were caused by viruses, with HSV contributing in 60 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/28\">",
"       28",
"      </a>",
"      ]. The incidence of HSV-1 infection after renal transplantation has ranged from 35 to 85 percent, depending upon the presence and amount of antibody to HSV and the level of immunosuppression required to prevent graft rejection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. Exogenous infection does not appear to be a factor in posttransplant HSV-1 infections.",
"     </li>",
"     <li>",
"      In an analysis of 40 patients undergoing chemotherapy for a variety of malignancies, the presence of HSV-1 in oral mucosa, as assessed by PCR, was detected in 70 percent prior to chemotherapy and 87.5 percent two weeks after initiation of the chemotherapeutic cycle. While 25 percent of patients manifested oral disease prior to starting chemotherapy, 65.7 percent of patients had oral mucosal changes at the second two-week assessment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a cohort of bone marrow transplant recipients, 82 percent of seropositive patients developed reactivation of HSV after transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/31\">",
"       31",
"      </a>",
"      ]. HSV infection in these patients was usually secondary to endogenous reactivation rather than primary infection; the presence of antibody to HSV in the donor did not affect the response of the recipient.",
"     </li>",
"     <li>",
"      The prevalence of HSV-1 cutaneous infections in HIV-infected patients is in the range of 5 to 20 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/32\">",
"       32",
"      </a>",
"      ]. Lesions tend to be more severe than in immunocompetent hosts, demonstrating local destruction and persistent shedding of virus. In addition, the incidence of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      resistance in immunocompromised patients is higher than in the general population. In contrast to cutaneous infection, the incidence of herpetic keratitis in HIV-infected patients is similar to that in the HIV-negative population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/8/38021/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24975914\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HSV-1 is transmitted from person-to-person via infected oral secretions during close contact. Infection occurs worldwide, equally between the sexes, and without seasonal variation. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incubation period of oral infections ranges from 1 to 26 days (median 6 to 8 days) and lesions range from 1 to 8 days in duration. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Contact with herpetic lesions or oral secretions can produce infection with HSV-1 [2]. The viral titer is 100 to 1000 times greater when lesions are present; as a result, transmission is much more likely when the patient is symptomatic. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Worldwide, more than 90 percent of people are seropositive for HSV-1 by the fourth decade of life, especially those of lower socioeconomic groups. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Seroepidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cutaneous and ocular HSV-1 infections have been recognized as a health risk for athletes involved in contact sports and for healthcare workers. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Populations at risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incidence of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      -resistant HSV is more common in the immunocompromised host than in the normal host. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'The immunocompromised host'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38021/abstract/1\">",
"      Scott DA, Coulter WA, Lamey PJ. Oral shedding of herpes simplex virus type 1: a review. J Oral Pathol Med 1997; 26:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38021/abstract/2\">",
"      Douglas RG Jr, Couch RB. A prospective study of chronic herpes simplex virus infection and recurrent herpes labialis in humans. J Immunol 1970; 104:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38021/abstract/3\">",
"      Corey L, Spear PG. Infections with herpes simplex viruses (1). N Engl J Med 1986; 314:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38021/abstract/4\">",
"      Claou&eacute; C, De Cock R. The spectrum of herpes simplex virus disease of the anterior segment in the 1990s. Acta Ophthalmol Scand 1996; 74:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38021/abstract/5\">",
"      BUDDINGH GJ, SCHRUM DI, LANIER JC, GUIDRY DJ. Studies of the natural history of herpes simplex infections. Pediatrics 1953; 11:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38021/abstract/6\">",
"      Spruance SL, Overall JC Jr, Kern ER, et al. The natural history of recurrent herpes simplex labialis: implications for antiviral therapy. N Engl J Med 1977; 297:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38021/abstract/7\">",
"      Young SK, Rowe NH, Buchanan RA. A clinical study for the control of facial mucocutaneous herpes virus infections. I. Characterization of natural history in a professional school population. Oral Surg Oral Med Oral Pathol 1976; 41:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38021/abstract/8\">",
"      Brandt BM, Mandleblatt J, Asbell PA. Risk factors for herpes simplex-induced keratitis: a case-control study. Ann Ophthalmol 1994; 26:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38021/abstract/9\">",
"      Remeijer L, Maertzdorf J, Doornenbal P, et al. Herpes simplex virus 1 transmission through corneal transplantation. Lancet 2001; 357:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38021/abstract/10\">",
"      Roberts CM, Pfister JR, Spear SJ. Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sex Transm Dis 2003; 30:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38021/abstract/11\">",
"      Roberts C. Genital herpes in young adults: changing sexual behaviours, epidemiology and management. Herpes 2005; 12:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38021/abstract/12\">",
"      Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006; 296:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38021/abstract/13\">",
"      Malvy D, Halioua B, Lan&ccedil;on F, et al. Epidemiology of genital herpes simplex virus infections in a community-based sample in France: results of the HERPIMAX study. Sex Transm Dis 2005; 32:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38021/abstract/14\">",
"      Horowitz R, Aierstuck S, Williams EA, Melby B. Herpes simplex virus infection in a university health population: clinical manifestations, epidemiology, and implications. J Am Coll Health 2011; 59:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38021/abstract/15\">",
"      Langenberg AG, Corey L, Ashley RL, et al. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med 1999; 341:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38021/abstract/16\">",
"      Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. Clin Infect Dis 1998; 26:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38021/abstract/17\">",
"      Blackwelder WC, Dolin R, Mittal KK, et al. A population study of herpesvirus infections and HLA antigens. Am J Epidemiol 1982; 115:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38021/abstract/18\">",
"      Belongia EA, Goodman JL, Holland EJ, et al. An outbreak of herpes gladiatorum at a high-school wrestling camp. N Engl J Med 1991; 325:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38021/abstract/19\">",
"      Nahmias AJ, Roizman B. Infection with herpes-simplex viruses 1 and 2. 3. N Engl J Med 1973; 289:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38021/abstract/20\">",
"      Perl TM, Haugen TH, Pfaller MA, et al. Transmission of herpes simplex virus type 1 infection in an intensive care unit. Ann Intern Med 1992; 117:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38021/abstract/21\">",
"      Buchman TG, Roizman B, Adams G, Stover BH. Restriction endonuclease fingerprinting of herpes simplex virus DNA: a novel epidemiological tool applied to a nosocomial outbreak. J Infect Dis 1978; 138:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38021/abstract/22\">",
"      Brown ZA, Selke S, Zeh J, et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med 1997; 337:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38021/abstract/23\">",
"      Hashido M, Lee FK, Nahmias AJ, Kawana T. Prevalence of herpes simplex virus type 1- and 2- specific antibodies among the acute, recurrent, and provoked types of female genital herpes. Microbiol Immunol 1997; 41:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38021/abstract/24\">",
"      Sullivan-Bolyai J, Hull HF, Wilson C, Corey L. Neonatal herpes simplex virus infection in King County, Washington. Increasing incidence and epidemiologic correlates. JAMA 1983; 250:3059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38021/abstract/25\">",
"      Ship, H, Morris, AL, Durocher, RT, Burker, LW. Recurrent aphthous ulcerations and recurrent herpes labialis in a professional school student population. Oral Surg 1960; 13:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38021/abstract/26\">",
"      Cook SD. Herpes simplex virus in the eye. Br J Ophthalmol 1992; 76:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38021/abstract/27\">",
"      Lafferty WE, Coombs RW, Benedetti J, et al. Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. N Engl J Med 1987; 316:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38021/abstract/28\">",
"      Reis MA, Costa RS, Ferraz AS. Causes of death in renal transplant recipients: a study of 102 autopsies from 1968 to 1991. J R Soc Med 1995; 88:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38021/abstract/29\">",
"      Naraqi S, Jackson GG, Jonasson O, Yamashiroya HM. Prospective study of prevalence, incidence, and source of herpesvirus infections in patients with renal allografts. J Infect Dis 1977; 136:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38021/abstract/30\">",
"      Djuric M, Pavlica D, Jankovic L, et al. Presence of herpes simplex virus on the oral mucosa in patients undergoing chemotherapy. Scott Med J 2007; 52:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38021/abstract/31\">",
"      Meyers JD, Flournoy N, Thomas ED. Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. J Infect Dis 1980; 142:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38021/abstract/32\">",
"      Itin PH, Lautenschlager S. Viral lesions of the mouth in HIV-infected patients. Dermatology 1997; 194:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38021/abstract/33\">",
"      Hodge WG, Margolis TP. Herpes simplex virus keratitis among patients who are positive or negative for human immunodeficiency virus: an epidemiologic study. Ophthalmology 1997; 104:120.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8333 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-9C35C7E240-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_8_38021=[""].join("\n");
var outline_f37_8_38021=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24975914\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SEROEPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Populations at risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HSV-1 RECURRENCE PATTERNS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      THE IMMUNOCOMPROMISED HOST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24975914\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=related_link\">",
"      Clinical manifestations and diagnosis of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/12/33992?source=related_link\">",
"      Herpes simplex keratitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_8_38022="Waldeyers ring";
var content_f37_8_38022=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75111%7EPC%2F65825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75111%7EPC%2F65825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Waldeyer's ring",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 347px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Waldeyer's ring is the ring of lymphoid tissue in the pharynx formed by the palatine tonsils, pharyngeal tonsils, tubal tonsils, and lingual tonsils.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tonsils in mid-sagittal section through pharynx",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 435px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_8_38022=[""].join("\n");
var outline_f37_8_38022=null;
var title_f37_8_38023="St. Louis encephalitis";
var content_f37_8_38023=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   St. Louis encephalitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/8/38023/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/8/38023/contributors\">",
"     Thomas P Monath, MD, FACP, FASTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/8/38023/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/8/38023/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/8/38023/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/8/38023/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/8/38023/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;St. Louis encephalitis (SLE) is an acute, mosquito-borne viral illness characterized by meningeal and brain parenchymal inflammation and injury. The disease occurs in endemic and epidemic form in North and South America. Epidemics of SLE in the United States have been responsible for at least 1,000,000 mild or subclinical infections, 10,000 clinical cases, and 1000 deaths in the United States since SLE virus was first isolated in 1933 during an outbreak in St. Louis, Missouri [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of SLE virus evolution indicate that the virus was introduced into North America from tropical America in the late 19th Century [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/2\">",
"     2",
"    </a>",
"    ]. There is evidence that West Nile virus, which was introduced into the United States in 1999, is displacing SLE in some areas by more efficient transmission and cross-protective immunity in wild birds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VIROLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;St. Louis encephalitis virus is a member of the family Flaviviridae, a group of small (40 to 60 nm), enveloped, positive-sense, single-stranded RNA viruses that replicate in the cytoplasm of infected cells. Other members of this virus family include West Nile virus, Japanese encephalitis virus, Murray Valley encephalitis virus, yellow fever virus, and dengue virus. St. Louis encephalitis virus grows in a wide variety of avian and mammalian cell cultures and causes lethal encephalitis in infant mice or hamsters after intracerebral inoculation. SLE virus is antigenically closely related to West Nile virus, which causes a similar disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/54/38760?source=see_link\">",
"     \"Arthropod-borne encephalitides\"",
"    </a>",
"    .) This may result in diagnostic confusion, particularly if non-specific serological tests are used. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    SLE virus strains from the eastern and western United States and from tropical America are distinguishable at the nucleotide sequence level into at least six lineages and multiple clades [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/2,4-6\">",
"     2,4-6",
"    </a>",
"    ] and differ with respect to the mosquito vectors responsible for transmission and virulence for animal models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/7\">",
"     7",
"    </a>",
"    ]. The SLE virus Lineage II present east of the Mississippi river has been associated with severe epidemics, has the highest virulence for laboratory animals, and the highest case-fatality rate for humans. While there is evidence for geographic separation and local persistence (through overwintering), particularly In California (Lineage I), analyses of SLE virus evolution suggests flow of neotropical strains, particularly from northern Central America, Mexico, and the Caribbean, into the US by the agency of migratory birds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike other epidemic viral encephalitides in the United States, such as West Nile and eastern and western equine encephalitis, SLE rarely causes disease in horses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;After inoculation of the virus into the human host via mosquito saliva, viral replication is initiated in local tissues and regional lymph nodes. Subsequent spread occurs initially to extraneural tissues via the lymphatics and blood. SLE virus replicates in a wide array of cell types, including connective tissue, skeletal muscle, exo- and endocrine glands, and reticuloendothelial tissues. Viremia is terminated approximately one week after infection by neutralizing antibodies and cytotoxic T cells.",
"   </p>",
"   <p>",
"    The mechanism by which SLE virus reaches the brain remains uncertain, but may include direct invasion at sites of compromised microvasculature or at the choroid plexus, where the endothelium is \"fenestrated\". In animal models, olfactory neurons became infected early during the course of viremic infection, with subsequent axonal transport of virions to the olfactory lobe of the brain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/8\">",
"     8",
"    </a>",
"    ]. After the virus reaches the brain, infection spreads rapidly. Retrograde axonal transport from peripheral nerves to the spinal cord [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/9\">",
"     9",
"    </a>",
"    ] may explain the occurrence of myelitis in cases of SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/10\">",
"     10",
"    </a>",
"    ]. As shown for West Nile virus in the mouse model, immune activation (through toll-like receptor 3) may play a critical role in neuroinvasion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neuronal damage is probably mediated in part by caspase-3-dependent apoptosis, as shown for West Nile, JE and other flaviviruses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/12\">",
"     12",
"    </a>",
"    ]. The increased susceptibility of elderly persons to SLE virus (see below) may be due to mechanical factors (eg, hypertension, atherosclerosis) that compromise the integrity of the blood-brain barrier or to reduced immune responsiveness. Over-activity of angiotensin I-converting enzyme (ACE-1) in advanced age may exacerbate a pathological host response to infection, as suggested for West Nile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/13\">",
"     13",
"    </a>",
"    ]. Increased production of ACE-1 results in increased angiotensin II, a powerful pro-inflammatory cytokine.",
"   </p>",
"   <p>",
"    Most infections with SLE are subclinical. The hereditary and acquired factors responsible for overt and severe infection in a small subset of patients remain unknown. Susceptibility of mice to flavivirus infection has been linked to genes controlling 2',5' oligoA synthetase, the antiviral factor induced by interferon, but the role of this gene in humans is uncertain. Genetic susceptibility to fatal infection with West Nile virus in humans was linked to homozygosity for CCR5Delta32, a nonfunctional variant of chemokine receptor CCR5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/14\">",
"     14",
"    </a>",
"    ]. A fatal case of another flavivirus infection (yellow fever vaccine-associated viscerotropic disease) was also associated with a possible defect in CCR5 and its ligand RANTES, which might have altered trafficking of CD8+ cells important to the antiviral immune response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/15\">",
"     15",
"    </a>",
"    ]. Experimental studies of West Nile infection indicate that trafficking of specific CD8+ T cells to the brain is critical to recovery and survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recovery from infection is mediated by neutralizing antibodies and CD8+ T cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/17\">",
"     17",
"    </a>",
"    ]. In cases with CNS infections, CD8+ T cells are recruited across the blood-brain barrier to clear virus from brain tissue. This appears to be under the control of the cytokine CXCR4 on endothelial cells and its receptor CXCR4 on lymphocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/16\">",
"     16",
"    </a>",
"    ]. Infection with SLE virus results in a long-lasting neutralizing antibody response that is responsible for protection against reinfection.",
"   </p>",
"   <p>",
"    Chronic infection with SLE has been demonstrated in hamsters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/18\">",
"     18",
"    </a>",
"    ], but there are no data indicating that this occurs in humans. Chronic infections of humans, with neurological consequences, have nevertheless been reported for related flaviviruses (JE and tick-borne encephalitis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;SLE produces a lymphocytic meningitis; pathologic changes in the brain, particularly the gray matter, include perivascular lymphocytic infiltrates, cellular nodules, and neuronal degeneration. While lesions are distributed throughout the brain, the most severely affected regions are the hypothalamus, cerebellar and cerebral cortex, basal ganglia, brainstem and cervical spinal cord [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/10,19\">",
"     10,19",
"    </a>",
"    ]. Rarely, SLE may present as acute demyelinating encephalomyelitis (ADEM) with prominent lesions in white matter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/20\">",
"     20",
"    </a>",
"    ]. Pathologic changes in extraneural tissues have not been described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;SLE virus is widely distributed in the Americas. It is the second leading cause of epidemic viral encephalitis in the United States after West Nile virus. In typical years, tens to hundreds of human cases are reported and, in exceptional epidemic years, almost 3000 cases have been reported. Epidemics have occurred principally in the Ohio-Mississippi valley, eastern Texas and Florida, and occasionally in southeastern Canada and northern Mexico. Prior to 2005, only sporadic cases were reported from tropical America. However there have been recent reports of epidemics in both Argentina and Brazil caused by Lineage III SLE virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SLE occurs during the summer months when mosquito vectors are active and peaks during August and September. Transmission may occur as late as December in warmer climates, such as Florida and southern California. Prior infection with dengue virus does not cross-protect against SLE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Transmission cycle",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States and contiguous areas, SLE virus is transmitted by several species of Culex vector mosquitoes. The intermediate hosts are wild birds, principally small passerine species. Humans are tangentially infected by mosquitoes that have fed on viremic birds and are dead-end hosts with respect to the transmission cycle. An extrinsic incubation period of 7 to 10 days is required in the mosquito vector between feeding on a viremic bird and infectivity for a second host. This interval is shortened by high environmental temperature. Compared to West Nile virus, SLE infection of wild birds results in a lower viremia; this fact and a narrower avian host range for the virus explain the lower transmission rates and incidence of human infection.",
"   </p>",
"   <p>",
"    The biting habits and distribution of mosquito vector species, as well as virulence properties of the virus, are responsible for epidemiologic differences between the disease in different geographic regions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the eastern United States (except Florida), the principal epidemic vectors are two closely related mosquito species (Culex pipiens and Culex quinquefasciatus) that breed ubiquitously in drainage ditches and other collections of polluted water in urban-suburban habitats. Vector densities may be high, and the mosquito bites in and around houses.",
"     </li>",
"     <li>",
"      In Florida, Culex nigripalpus is the principal vector which breeds in a wide variety of habitats, including swamps and drainage ditches. This mosquito bites mainly outdoors and may attain relatively high densities in wooded suburban habitats and parks in cities.",
"     </li>",
"     <li>",
"      In the western United States, SLE virus is transmitted by Culex tarsalis, which breeds in irrigated farmland. Human infections tend to occur in a sporadic or endemic pattern linked to outdoor exposure in rural areas where the enzootic cycle is maintained. In suburban and urban environments, Culex pipiens and Culex quinquefasciatus may be responsible for transmission.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    SLE virus can be found every summer in mosquitoes and birds in the United States, but outbreaks have often occurred at intervals of 3 to 10 years, often affecting different localities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/23\">",
"     23",
"    </a>",
"    ]. The ecologic reasons for the increased virus amplification in epidemic years remain obscure but probably involve a confluence of factors including rainfall and environmental temperature patterns which affect mosquito and avian host density and virus transmission rate. In the eastern US, spring to early summer drought conditions favor breeding of Culex vectors in concentrated sites. This also attracts congregation of avian hosts; summer rains expand vector populations and have been associated with SLE outbreaks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laboratory-acquired infection by aerosol exposure has been extremely rare. The virus is not shed in human secretions, and there are no recorded instances of person-to-person spread. SLE antigen is found in the urine of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/25\">",
"     25",
"    </a>",
"    ], but this is unlikely to be associated with transmission. The virus is not found in blood after the appearance of neurologic signs, and blood does not pose a significant infectious hazard in hospitals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;SLE is a reportable infection, with more than 10,000 SLE cases having been reported in the United States over the last five decades. The annual incidence has varied from 0.003 to 0.752 per 100,000 population with a median number of approximately 35 reported cases per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/23,26\">",
"     23,26",
"    </a>",
"    ]. In 1975, the largest SLE outbreak occurred in 1975 involving 2800 cases in 31 states.",
"   </p>",
"   <p>",
"    Attack rates during epidemics in the eastern United States have ranged widely from 5 to 200 per 100,000 people. The highest attack rates have been reported in outbreaks affecting small towns.",
"   </p>",
"   <p>",
"    Immunity to SLE in human populations in the United States is between one and six percent but may be as high as 15 percent in areas where outbreaks recently occurred. In most of the United States, naturally acquired immunity is not a significant barrier to epidemic spread.",
"   </p>",
"   <p>",
"    The emergence in 1999 of the antigenically-related West Nile virus and spread of this virus across the country in succeeding years raises the possibility of immunologic interactions between these two viruses. West Nile is strongly cross-protective against SLE in shared avian host species and is transmitted more efficiently by vectors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/3,27\">",
"     3,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human infection with SLE virus only rarely results in clinical illness. The average ratio of symptomatic illness to asymptomatic infection is 1:300 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/23\">",
"     23",
"    </a>",
"    ]. The most important risk factor for the development of symptomatic encephalitis is age, with elderly persons at highest risk. As an example the ratio of symptomatic to asymptomatic infection in children is 1:800 compared to a high of 1:85 in adults over the age of 60 years. The reason for this age-related susceptibility has not been defined. The disease is rare in children; the youngest reported case is in a 19-day old infant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/28\">",
"     28",
"    </a>",
"    ]. Concomitant HIV infection did not affect the clinical presentation in one small study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among symptomatic patients, the incubation period for SLE has been estimated to be 4 to 21 days. The spectrum of clinical illness includes nonspecific fever with headache, aseptic meningitis, and fatal meningoencephalitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. The severity of encephalitis and its lethality are greatest in the elderly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/23,30\">",
"     23,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Prodromal symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the appearance of central nervous system (CNS) signs, the patient with SLE virus infection experiences fever, generalized malaise, headache, and myalgias. Some patients have respiratory (cough, sore throat) or urinary tract (dysuria, urgency, incontinence) symptoms. Fever generally lasts for four to five days and may reach 40 to 41&ordm;C. The headache is typically severe and may be accompanied by photophobia, nausea, and vomiting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Neurologic signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The appearance of CNS signs is generally rapid. Children and young adults often experience a milder case of SLE, with signs of meningitis only. In more severe cases with global brain parenchymal involvement, patients exhibit altered sensorium and a wide array of neurologic abnormalities. Tremors of the eyelids, tongue, lips and extremities occur in as many as two-thirds of patients with SLE and may persist for weeks after recovery from the acute illness. Cranial nerve dysfunction occurs in 25 percent of patients, most frequently as unilateral facial motor weakness. Other signs include loss of oculomotor function, dysarthria, and rarely loss of the olfactory sense.",
"   </p>",
"   <p>",
"    Signs of thalamus, brainstem or cerebellum infection include tremors, myoclonus, opsoclonus, nystagmus and ataxia. Pathologic reflexes are common, but motor and sensory deficits are rare. Focal or generalized seizures have been noted in fewer than 10 percent of cases. Signs of severe increased intracranial pressure have not been reported.",
"   </p>",
"   <p>",
"    Post-infectious autoimmune syndromes have been rarely linked to SLE infection. There are two case reports of SLE presenting with a clinical diagnosis of Guillain-Barr&eacute; syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/32\">",
"     32",
"    </a>",
"    ]. There is also one case report of acute disseminated encephalomyelitis (ADEM) following three weeks after mild SLE infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral white blood cell (WBC) count is normal or may be mildly elevated, particularly in children. Alanine aminotransferase and creatine phosphokinase levels are modestly elevated in 50 to 75 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/30\">",
"     30",
"    </a>",
"    ]. Proteinuria, microscopic hematuria, pyuria, and mild azotemia are also found in some patients. It is not likely that these findings are related to the infection, as St. Louis encephalitis viral antigen was found in urinary sediment in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/25\">",
"     25",
"    </a>",
"    ] and the kidney is a target organ of infection in an animal model [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/18\">",
"     18",
"    </a>",
"    ]. Hyponatremia with fluid overload due to the inappropriate secretion of antidiuretic hormone (SIADH) has been documented in approximately 30 percent of patients; the syndrome is mild, and patients respond to water restriction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cerebrospinal fluid analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most consistent laboratory abnormalities are found in the cerebrospinal fluid (CSF). The lumbar puncture opening pressure is mildly elevated at 200 to 250 mmHg in approximately one-third of cases. CSF protein concentrations are mildly elevated at 45 to 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and rarely exceed 200",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    while the glucose concentrations are normal or mildly depressed. The WBC count in the CSF can vary from a few to several hundred cells, but counts exceeding 500",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    are very rare. The proportion of mononuclear cells increases from 40 to 50 percent in CSF obtained during the initial illness to more than 80 percent by day seven. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/10/17576?source=see_link\">",
"     \"Cerebrospinal fluid: Physiology and utility of an examination in disease states\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Electroencephalography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electroencephalography (EEG) shows diffuse generalized slowing and delta wave activity; occasionally focal discharges and spike activity can be seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/31\">",
"     31",
"    </a>",
"    ]. If EEG abnormalities are present, they do not appear to correlate well with the severity of clinical symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;In typical cases of SLE, no specific abnormalities have been identified on brain scans, computed tomographic scans, or magnetic resonance images; cortical edema, pathologic enhancement, and mass effect are not present. The case report of ADEM noted above that was due to SLE virus was notable for white matter signal abnormalities on magnetic nuclear imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of cerebral blood flow and metabolism in comatose patients with St. Louis encephalitis showed reduced metabolic activity and oxygen uptake. However, blood flow was not affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     OUTCOME OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Death due to the virus generally occurs within the first two weeks of the onset of the infection, accompanied by coma and respiratory depression. The case-fatality rate is higher in persons over 60 years than in younger individuals (20 versus 3 to 6 percent). Case-fatality rates adjusted for age are also higher in the eastern than in the western United States, possibly reflecting differences in virulence of the viral strains.",
"   </p>",
"   <p>",
"    Direct injury to the brain by the virus causes death during the first two weeks of infection; later deaths are due to complications of hospitalization, especially bronchopneumonia and pulmonary embolism. Clinical features suggesting a poor prognosis include sustained high fever, convulsions, advanced age, and severely depressed state of consciousness. In some outbreaks, an association was noted between St. Louis encephalitis and a variety of underlying diseases, including hypertension, diabetes mellitus, alcoholism and chronic obstructive lung disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Convalescence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients, particularly elderly patients, experience difficulty in regaining full health after an episode of SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/33\">",
"     33",
"    </a>",
"    ]. A period of prolonged convalescence, lasting weeks or even months, is characterized by headaches, anxiety, irritability, memory deficits, persistent tremor, and dizziness. Objective signs on physical examination include tremors and asymmetric reflexes. Classical Parkinsonism has not been a feature of the convalescent syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;SLE should be considered in all cases of viral encephalitis occurring in the summertime, but particularly in elderly patients or when two or more similar cases cluster in a community. The most important agent causing confusion is West Nile virus, which produces a similar disease with a predilection for the elderly. SLE and West Nile infections must be distinguished by serologic tests the viruses contain cross-reactive antigens. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16088?source=see_link\">",
"     \"Epidemiology and pathogenesis of West Nile virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SLE has, in occasional cases, been mistaken for stroke, heat stroke, or drug overdose. When the primary manifestation is aseptic meningitis, SLE may be difficult to distinguish from enteroviral infections. Other viral, mycoplasma, and bacterial infections of the CNS can produce a similar clinical picture. By contrast, it is easier to differentiate typical cases of herpes simplex virus encephalitis from SLE because the former is characterized by a focal presentation, convulsions, early behavioral disturbances, and an increased CSF pressure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/1001?source=see_link\">",
"     \"Herpes simplex virus type 1 encephalitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically, SLE may be difficult to differentiate from other causes of summer season encephalitis, including West Nile. Flaccid paralysis and polio-like syndrome appear to be more common in West Nile. The diagnosis of SLE is generally made by serology, particularly the IgM enzyme linked immunosorbent assay (ELISA). The presence of IgM antibodies in a single serum provides a presumptive diagnosis, and a significant rise or fall between appropriately timed acute-convalescent or early-late convalescent sera is diagnostic. However, antigenic cross-reactions with other flaviviruses, particularly West Nile virus, can be a problem, although use of a discriminatory algorithm for analysis of IgM ELISA successfully differentiated the infections in one report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/34\">",
"     34",
"    </a>",
"    ]. Non-infectious recombinant virus-like particle antigens are useful as diagnostic reagents.",
"   </p>",
"   <p>",
"    A rapid microsphere-based IgM immunoassay has been developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/35\">",
"     35",
"    </a>",
"    ], which will be an important adjunct to the institution of antiviral therapy. This specific neutralization test may be necessary for definitive serologic diagnosis. In addition, recombinant virus-like particle antigens have been engineered to have reduced cross reactivity and may be used as antigens in serological diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/36\">",
"     36",
"    </a>",
"    ]. Chimeric viruses have also been developed for use in type-specific neutralization tests having SLE envelope proteins in a yellow fever 17D vector, and can be used at the BL2 containment level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/37\">",
"     37",
"    </a>",
"    ]. These chimeric viruses are distributed to public health laboratories by the Centers for Disease Control, Ft. Collins, CO. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16088?source=see_link\">",
"     \"Epidemiology and pathogenesis of West Nile virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is also valuable to submit CSF for antibody testing since the finding of IgM antibody in CSF indicates brain infection and local antibody production. Polymerase chain reaction (PCR) analysis of CSF to exclude HSV or enteroviral infection may also be useful.",
"   </p>",
"   <p>",
"    Virus isolation from the blood or CSF has generally been unsuccessful. However, the virus may be recovered from brain tissue, including the basal ganglia, cervical cord and cerebellum, following inoculation of mammalian or mosquito cell culture or baby mice. Viral antigen can also be detected by immunofluorescence in brain tissue sections. There are few data on the use of polymerase chain reaction for detection of SLE in clinical samples.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific antiviral therapy is of proven efficacy and corticosteroids are not indicated, except in the rare case of ADEM. Interferon alfa reduces mortality in mice when it is given either subcutaneously or by aerosol at the time of exposure to the virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/38\">",
"     38",
"    </a>",
"    ]. The potential efficacy of this approach in humans was evaluated in a pilot study in which 15 patients with SLE received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29576?source=see_link\">",
"     interferon alfa-2b",
"    </a>",
"    were compared to 17 untreated patients with SLE admitted to the same hospital during an outbreak [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/39\">",
"     39",
"    </a>",
"    ]. Interferon alfa-2b was associated with a reduced likelihood of persistence of quadriplegia, quadriparesis, or respiratory insufficiency after the first week of hospitalization (13 versus 65 percent) and after the second week (7 versus 29 percent). Transient neutropenia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mild hepatitis occurred in 11 treated patients. A randomized trial is required to better assess the potential efficacy of early interferon alfa therapy. Administration of high-titer antibody to animals and human patients with West Nile may be effective even after the establishment of brain infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/40\">",
"     40",
"    </a>",
"    ]. This treatment has not been tried with SLE. There are a number of promising small molecules under investigation for treatment of dengue and West Nile, but the work is at an early stage and beyond the scope of this review. Antisense (RNAi) has also shown promise in animal models, although there are daunting delivery issues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38023/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal supportive management of patients requires attention to electrolyte and fluid balance, with water restriction, if necessary, to correct hyponatremia due to the syndrome of inappropriate ADH secretion and to prevent brain edema. Other measures may help to prevent nosocomial complications, such as nasogastric suction to reduce the risk of aspiration, skin care, prevention of deep vein thrombosis,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    to prevent gastric ulcer, and steps to reduce the risk of bacterial superinfections of the respiratory and urinary tracts. Mechanical ventilation may be required in patients with respiratory failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no available vaccine against SLE virus, although several experimental approaches have shown promise, including chimeric attenuated virus vectors using yellow fever 17D and vesicular stomatitis viruses. Some states and counties at historical risk of SLE undertake routine surveillance of virus activity using sentinel chickens (tested at intervals for serologic conversion) or mosquito collections for virus testing. The object of such testing is to observe potential virus transmission between birds and mosquitoes and initiate mosquito control measures in advance of the appearance of human cases. Mosquito control is also indicated to interrupt transmission once human cases appear. Remaining indoors in properly screened areas during the late afternoon and evening may significantly reduce the risk of mosquito bites in areas where SLE cases have occurred in the past.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4928852\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      St. Louis encephalitis virus is a member of the family Flaviviridae, which includes West Nile virus, Japanese encephalitis virus, yellow fever virus, and dengue virus. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Virology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After inoculation of the virus into the human host via mosquito saliva, viral replication is initiated in local tissues and regional lymph nodes. Subsequent spread occurs initially to extraneural tissues via the lymphatics and blood. The mechanism by which SLE virus reaches the brain remains uncertain, but may include direct invasion at sites of compromised microvasculature or at the choroid plexus, where the endothelium is \"fenestrated\". Immune activation may play a critical role in neuroinvasion. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SLE virus is widely distributed in the Americas. It is the second leading cause of epidemic viral encephalitis in the United States after West Nile virus. SLE mainly occurs during the summer months when mosquito vectors are active. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Human infection with SLE virus only rarely results in clinical illness. The most important risk factor for symptomatic encephalitis is older age. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms of St. Louis encephalitis include a prodrome of fever, malaise, headache, and myalgias, followed by changes in sensorium. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cerebral spinal fluid (CSF) protein concentrations are mildly elevated at 45 to 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      while the glucose concentrations are normal or mildly depressed. The white blood cell count in the CSF can vary from a few to several hundred cells, but counts exceeding 500",
"      <span class=\"nowrap\">",
"       cells/mm3",
"      </span>",
"      are rare. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Cerebrospinal fluid analysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The case-fatality rate is higher in persons over 60 years than in younger individuals. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Outcome of infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no specific antiviral treatment or vaccine for St. Louis encephalitis. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/1\">",
"      Reisen WK. Epidemiology of St. Louis encephalitis virus. Adv Virus Res 2003; 61:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/2\">",
"      Baillie GJ, Kolokotronis SO, Waltari E, et al. Phylogenetic and evolutionary analyses of St. Louis encephalitis virus genomes. Mol Phylogenet Evol 2008; 47:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/3\">",
"      Reisen WK, Lothrop HD, Wheeler SS, et al. Persistent West Nile virus transmission and the apparent displacement St. Louis encephalitis virus in southeastern California, 2003-2006. J Med Entomol 2008; 45:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/4\">",
"      Kramer LD, Chandler LJ. Phylogenetic analysis of the envelope gene of St. Louis encephalitis virus. Arch Virol 2001; 146:2341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/5\">",
"      May FJ, Li L, Zhang S, et al. Genetic variation of St. Louis encephalitis virus. J Gen Virol 2008; 89:1901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/6\">",
"      Auguste AJ, Pybus OG, Carrington CV. Evolution and dispersal of St. Louis encephalitis virus in the Americas. Infect Genet Evol 2009; 9:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/7\">",
"      Trent DW, Monath TP, Bowen GS, et al. Variation among strains of St. Louis encephalitis virus: basis for a genetic, pathogenetic, and epidemiologic classification. Ann N Y Acad Sci 1980; 354:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/8\">",
"      Monath TP, Cropp CB, Harrison AK. Mode of entry of a neurotropic arbovirus into the central nervous system. Reinvestigation of an old controversy. Lab Invest 1983; 48:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/9\">",
"      Samuel MA, Wang H, Siddharthan V, et al. Axonal transport mediates West Nile virus entry into the central nervous system and induces acute flaccid paralysis. Proc Natl Acad Sci U S A 2007; 104:17140.",
"     </a>",
"    </li>",
"    <li>",
"     Gardner JJ, Reyes MG. Pathology. In: St. Louis Encephalitis, Monath TP (Ed), American Public Health Association, Washington, DC 1980. p.551.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/11\">",
"      Wang T, Town T, Alexopoulou L, et al. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med 2004; 10:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/12\">",
"      Samuel MA, Morrey JD, Diamond MS. Caspase 3-dependent cell death of neurons contributes to the pathogenesis of West Nile virus encephalitis. J Virol 2007; 81:2614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/13\">",
"      Moskowitz DW, Johnson FE. The central role of angiotensin I-converting enzyme in vertebrate pathophysiology. Curr Top Med Chem 2004; 4:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/14\">",
"      Lim JK, Louie CY, Glaser C, et al. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J Infect Dis 2008; 197:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/15\">",
"      Pulendran B, Miller J, Querec TD, et al. Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis 2008; 198:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/16\">",
"      McCandless EE, Zhang B, Diamond MS, Klein RS. CXCR4 antagonism increases T cell trafficking in the central nervous system and improves survival from West Nile virus encephalitis. Proc Natl Acad Sci U S A 2008; 105:11270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/17\">",
"      Shrestha B, Ng T, Chu HJ, et al. The relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virus. Vaccine 2008; 26:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/18\">",
"      Siirin MT, Duan T, Lei H, et al. Chronic St. Louis encephalitis virus infection in the golden hamster (Mesocricetus auratus). Am J Trop Med Hyg 2007; 76:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/19\">",
"      Suzuki M, Phillips CA. St. Louis encephalitis. A histopathologic study of the fatal cases from the Houston epidemic in 1964. Arch Pathol 1966; 81:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/20\">",
"      Sejvar JJ, Bode AV, Curiel M, Marfin AA. Post-infectious encephalomyelitis associated with St. Louis encephalitis virus infection. Neurology 2004; 63:1719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/21\">",
"      Spinsanti LI, D&iacute;az LA, Glatstein N, et al. Human outbreak of St. Louis encephalitis detected in Argentina, 2005. J Clin Virol 2008; 42:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/22\">",
"      Mondini A, Cardeal IL, L&aacute;zaro E, et al. Saint Louis encephalitis virus, Brazil. Emerg Infect Dis 2007; 13:176.",
"     </a>",
"    </li>",
"    <li>",
"     Monath TP. Epidemiology. In: St. Louis Encephalitis, Monath TP (Ed), American Public Health Association, Washington, DC 1980. p.239.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/24\">",
"      Shaman J, Day JF, Stieglitz M. The spatial-temporal distribution of drought, wetting, and human cases of St. Louis encephalitis in southcentral Florida. Am J Trop Med Hyg 2004; 71:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/25\">",
"      Luby JP, Murphy FK, Gilliam JN, et al. Antigenuria in St. Louis encephalitis. Am J Trop Med Hyg 1980; 29:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/26\">",
"      Monath TP, Tsai TF. St. Louis encephalitis: lessons from the last decade. Am J Trop Med Hyg 1987; 37:40S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/27\">",
"      Reisen WK, Fang Y, Martinez VM. Avian host and mosquito (Diptera: Culicidae) vector competence determine the efficiency of West Nile and St. Louis encephalitis virus transmission. J Med Entomol 2005; 42:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/28\">",
"      Wootton SH, Kaplan SL, Perrotta DM, et al. St. Louis encephalitis in early infancy. Pediatr Infect Dis J 2004; 23:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/29\">",
"      Okhuysen PC, Crane JK, Pappas J. St. Louis encephalitis in patients with human immunodeficiency virus infection. Clin Infect Dis 1993; 17:140.",
"     </a>",
"    </li>",
"    <li>",
"     Brinker KR, Monath TP. The acute disease. In: St. Louis Encephalitis, Monath TP (Ed), American Public Health Association, Washington, DC 1980. p.503.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/31\">",
"      Brinker KR, Paulson G, Monath TP, et al. St Louis encephalitis in Ohio, September 1975: clinical and EEG studies in 16 cases. Arch Intern Med 1979; 139:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/32\">",
"      Powell KE, Blakey DL. St. Louis encephalitis: clinical and epidemiologic aspects, Mississippi, 1974. South Med J 1976; 69:1121.",
"     </a>",
"    </li>",
"    <li>",
"     Finley KH, Riggs N. Convalescence and sequelae. In: St. Louis Encephalitis, Monath TP (Ed), American Public Health Association, Washington, DC 1980. p.535.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/34\">",
"      Martin DA, Noga A, Kosoy O, et al. Evaluation of a diagnostic algorithm using immunoglobulin M enzyme-linked immunosorbent assay to differentiate human West Nile Virus and St. Louis Encephalitis virus infections during the 2002 West Nile Virus epidemic in the United States. Clin Diagn Lab Immunol 2004; 11:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/35\">",
"      Johnson AJ, Noga AJ, Kosoy O, et al. Duplex microsphere-based immunoassay for detection of anti-West Nile virus and anti-St. Louis encephalitis virus immunoglobulin m antibodies. Clin Diagn Lab Immunol 2005; 12:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/36\">",
"      Roberson JA, Crill WD, Chang GJ. Differentiation of West Nile and St. Louis encephalitis virus infections by use of noninfectious virus-like particles with reduced cross-reactivity. J Clin Microbiol 2007; 45:3167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/37\">",
"      Pugachev KV, Guirakhoo F, Mitchell F, et al. Construction of yellow fever/St. Louis encephalitis chimeric virus and the use of chimeras as a diagnostic tool. Am J Trop Med Hyg 2004; 71:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/38\">",
"      Brooks TJ, Phillpotts RJ. Interferon-alpha protects mice against lethal infection with St Louis encephalitis virus delivered by the aerosol and subcutaneous routes. Antiviral Res 1999; 41:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/39\">",
"      Rahal JJ, Anderson J, Rosenberg C, et al. Effect of interferon-alpha2b therapy on St. Louis viral meningoencephalitis: clinical and laboratory results of a pilot study. J Infect Dis 2004; 190:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/40\">",
"      Makhoul B, Braun E, Herskovitz M, et al. Hyperimmune gammaglobulin for the treatment of West Nile virus encephalitis. Isr Med Assoc J 2009; 11:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38023/abstract/41\">",
"      Stein DA, Shi PY. Nucleic acid-based inhibition of flavivirus infections. Front Biosci 2008; 13:1385.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1288 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-F706DDF602-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_8_38023=[""].join("\n");
var outline_f37_8_38023=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4928852\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VIROLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Transmission cycle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Prodromal symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Neurologic signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cerebrospinal fluid analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Electroencephalography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      OUTCOME OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Convalescence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4928852\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/54/38760?source=related_link\">",
"      Arthropod-borne encephalitides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/10/17576?source=related_link\">",
"      Cerebrospinal fluid: Physiology and utility of an examination in disease states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16088?source=related_link\">",
"      Epidemiology and pathogenesis of West Nile virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/1001?source=related_link\">",
"      Herpes simplex virus type 1 encephalitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_8_38024="Neonatal HSV lung";
var content_f37_8_38024=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63300&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63300&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lung pathology in disseminated neonatal herpes simplex virus (HSV) infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 334px; height: 503px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Histopathologic slide (magnification 40X) of lung tissue from a neonate who died of disseminated HSV, showing pneumonitis and lung inclusion cells (arrows)&nbsp;characteristic of herpes virus infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Edwina Popek, DO, Department of Pathology, Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_8_38024=[""].join("\n");
var outline_f37_8_38024=null;
var title_f37_8_38025="Classic Kaposi sarcoma: Clinical features, staging, diagnosis, and treatment";
var content_f37_8_38025=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Classic Kaposi sarcoma: Clinical features, staging, diagnosis, and treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/contributors\">",
"     Susan E Krown, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/contributors\">",
"     Jasmeet Chadha Singh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/contributors\">",
"     Robert Maki, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/contributors\">",
"     Thomas F DeLaney, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/contributors\">",
"     June K Robinson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kaposi sarcoma (KS) is an angioproliferative disorder that requires infection with human herpes virus 8 (HHV-8), also known as Kaposi sarcoma-associated Herpes virus (KSHV), for its development [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. KS is classified into four types based upon the clinical circumstances in which it develops: classic (the type originally described by Kaposi, which typically presents in middle or old age), endemic (several forms described in sub-Saharan indigenous Africans prior to the AIDS epidemic), iatrogenic (a type associated with immunosuppressive drug therapy, typically seen in renal allograft recipients) and AIDS-associated (epidemic KS). The epidemiologic and clinical aspects of these four types of KS are compared in the table (",
"    <a class=\"graphic graphic_table graphicRef76370 \" href=\"mobipreview.htm?18/16/18700\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This review will focus on the clinical presentation, staging, diagnosis, and treatment of classic KS (CKS). The epidemiology, risk factors, pathology, and molecular pathogenesis of CKS are discussed elsewhere, as are AIDS-related KS and iatrogenic KS developing in the setting of immunosuppressive therapy. (See",
"    <a class=\"medical medical_review\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis?source=see_link\">",
"     \"Classic Kaposi sarcoma: Epidemiology, risk factors, pathology, and molecular pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/52/12103?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/37/18009?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Staging and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/23/34170?source=see_link&amp;anchor=H10#H10\">",
"     \"Development of malignancy following solid organ transplantation\", section on 'Kaposi's sarcoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classic Kaposi sarcoma (CKS) occurs most often in older men of Mediterranean or",
"    <span class=\"nowrap\">",
"     Central/Eastern",
"    </span>",
"    European ancestry, in whom the lesions usually occur on the distal extremities, particularly the lower legs and feet. (See",
"    <a class=\"medical medical_review\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis?source=see_link\">",
"     \"Classic Kaposi sarcoma: Epidemiology, risk factors, pathology, and molecular pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Skin lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;CKS is characterized by the appearance of purplish, reddish blue, or dark",
"    <span class=\"nowrap\">",
"     brown/black",
"    </span>",
"    macules, plaques, and nodules on the skin (",
"    <a class=\"graphic graphic_picture graphicRef81468 graphicRef69584 graphicRef54707 \" href=\"mobipreview.htm?33/34/34345\">",
"     picture 1A-C",
"    </a>",
"    ). Nodular lesions may ulcerate and bleed easily. The skin lesions range in size from very small to several centimeters in diameter, and they can remain unchanged for months to years, or grow rapidly within a few weeks and disseminate. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Natural history'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The dermatology literature contains reference to at least 10 different morphologic variants of the cutaneous lesions of KS, which are referred to as patch, plaque, nodular, lymphadenopathic (usually in African children), exophytic, infiltrative (the latter two in African adults with endemic KS), ecchymotic, telangiectatic, keloidal, and cavernous or lymphangioma-like variants [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/4\">",
"     4",
"    </a>",
"    ]. The cavernous- or lymphangioma-like variants are common in CKS, particularly in the setting of chronic lymphedema. In this variant, lesions develop on the lower extremities that consist of compressible nodules that appear to be fluid-filled cysts. Histologically, lymphangioma-like KS consists of anastomosing networks of smaller, irregular and compressible dilated lymphatics lined by flat and cytologically banal endothelial cells [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There may be accompanying lymphedema of the affected extremity. The lymphedema is not generally associated with the presence of bulky regional nodal disease, but instead, related to local dermal infiltration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dermal lymphatic involvement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/52/1866?source=see_link\">",
"     \"Clinical manifestations and diagnosis of lymphedema\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/1/33817?source=see_link\">",
"     \"Prevention and treatment of lymphedema\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Extracutaneous involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the course of the disease (rarely initially [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/8\">",
"     8",
"    </a>",
"    ]), mucous membranes of mouth and gastrointestinal (GI) tract and regional lymph nodes may be affected. GI tract involvement is usually asymptomatic, but bleeding, diarrhea, protein-losing enteropathy, intussusception, and perforation have been reported [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, GI",
"    <span class=\"nowrap\">",
"     tract/oral",
"    </span>",
"    mucosal involvement is less common than with AIDS-related KS, affecting &le;10 percent of patients [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/37/18009?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Staging and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, in one report, an extraordinary 82 percent of Greek patients (71 of 87) with biopsy-proven CKS who were investigated with upper gastrointestinal endoscopy had GI lesions; all 71 had stomach lesions, 19 had esophageal lesions, eight had lesions of the proximal duodenum, and two had both esophageal and duodenal lesions [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/14\">",
"     14",
"    </a>",
"    ]. Although this finding could be interpreted as suggesting the need for screening endoscopy in patients with newly diagnosed CKS, it also supports the view that the presence of asymptomatic GI involvement probably has little effect on prognosis. In practice, routine endoscopy is not performed in people diagnosed with CKS who do not have symptoms referable to the GI tract.",
"   </p>",
"   <p>",
"    Regional nodal involvement is relatively uncommon and it is rarely bulky. Nodal involvement was reported in 15 percent of 66 Greek patients with CKS in one study [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/11\">",
"     11",
"    </a>",
"    ]. The presence of nodal disease probably does not worsen overall prognosis, although this has been demonstrated in AIDS-related KS, not classic KS.",
"   </p>",
"   <p>",
"    Involvement of visceral organs other than the lining of the alimentary tract (eg, lung, liver, bone, bone marrow) is extremely rare [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/11,15-17\">",
"     11,15-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, CKS has a chronic, indolent course, and it rarely influences survival. Given the affected age group, death from unrelated causes is more common [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. As an example, in a series of 438 American patients with CKS who were followed for an average of 4.8 years, 24 percent died of second malignancies, 22 percent died of other medical conditions, and only 2 percent died of widespread disease [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Yet, the disease occasionally has an acute onset and rapidly progressive course, or previously indolent disease can undergo sudden worsening, leading to disability and even death [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/18,19,22\">",
"     18,19,22",
"    </a>",
"    ]. In fact, Kaposi&rsquo;s original 1872 paper described the disease as \"incurable and deadly\", stating that \"the disease leads to death and it does so within a short period of two to three years\" [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Classic Kaposi sarcoma (CKS) is usually suspected based upon the appearance of the characteristic lesions (purplish, reddish blue, or dark",
"    <span class=\"nowrap\">",
"     brown/black",
"    </span>",
"    patches, plaques or nodules) and their distribution (on the skin, most often of the lower extremities).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the lower extremity, the lesions can be mistaken for the skin lesions of peripheral vascular disease, a condition which is common in the elderly patients who are at greatest risk for CKS.",
"   </p>",
"   <p>",
"    Other lesions which may mimic the appearance of CKS include bacillary angiomatosis, angiosarcoma, and benign vascular lesions, such as hemangiomas. Bacillary angiomatosis is caused by Bartonella species, a slow-growing, fastidious, gram-negative bacillus, and is readily treated with antibiotic therapy. The skin lesions of bacillary angiomatosis usually appear as numerous small red to purple papules that may gradually expand into large pedunculated lesions or nodules that may become friable. The rash may be associated with symptoms such as fever, chills, malaise, headache, and anorexia. S. schenckii (sporotrichosis) and M. marinum skin infections could also be confused with the nodular form of Kaposi sarcoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36583?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of Bartonella quintana infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/11/12469?source=see_link\">",
"     \"Clinical features and diagnosis of sporotrichosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24089?source=see_link\">",
"     \"Epidemiology of nontuberculous mycobacterial infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of less common dermatologic lesions may also be mistaken for CKS [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsy is required for definitive diagnosis. In addition to observing typical histological features on standard microscopy, polymerase chain reaction can be performed of the skin lesions to detect amplified HHV-8 DNA sequences, and immunohistochemical staining of biopsy specimens can also be performed to detect the presence of HHV-8 latency-associated nuclear antigen (LANA-1) within the spindle cells, thus confirming the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis?source=see_link\">",
"     \"Classic Kaposi sarcoma: Epidemiology, risk factors, pathology, and molecular pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Radiographic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic patients with CKS rarely require radiographic evaluation of the affected extremity because of the chronic usually indolent course. Screening for distant organ involvement is not needed due to the low frequency of radiographically evident metastatic disease. When present, mucosal involvement of the GI tract is not generally visible on radiographic studies. As noted above, patients with symptoms referable to the GI tract should be considered for endoscopy to evaluate for visceral mucosal involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to AIDS-related KS, there is no commonly used or universally agreed upon staging system for CKS. The American Joint Committee on Cancer (AJCC) TNM staging system for soft tissue sarcomas specifically excludes KS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/37/18009?source=see_link&amp;anchor=H432035701#H432035701\">",
"     \"AIDS-related Kaposi sarcoma: Staging and treatment\", section on 'Staging and evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the variable natural history of CKS, one group of investigators used their experience with 300 CKS patients to derive a proposed staging system, based upon disease distribution and the clinical pace of progression [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage I (maculonodular stage) &mdash; Small macules and nodules primarily confined to the lower extremities",
"     </li>",
"     <li>",
"      Stage II (infiltrative stage) &mdash; Plaques mainly involving lower extremities, sometimes associated with a few nodules",
"     </li>",
"     <li>",
"      Stage III (florid stage) &mdash; Multiple angiomatous plaques and nodules involving the lower extremities that are often ulcerated",
"     </li>",
"     <li>",
"      Stage IV (disseminated stage) &mdash; Multiple angiomatous nodules and plaques extending beyond the lower extremities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Stage I to III disease was further subdivided into slow (group A) or rapid disease progression (group B, defined as an increase in the total number of",
"    <span class=\"nowrap\">",
"     plaques/nodules",
"    </span>",
"    or in the total area of plaques in the three months following an examination); all patients with stage IV disease were considered to have rapidly progressive disease.",
"   </p>",
"   <p>",
"    In the original series of 300 patients, those classified as having stages I or II disease had a slower rate of progression, fewer complications, and a lower occurrence of GI",
"    <span class=\"nowrap\">",
"     tract/visceral",
"    </span>",
"    involvement. In contrast, patients with stage III or IV disease had more rapid disease progression and a greater likelihood of GI",
"    <span class=\"nowrap\">",
"     tract/visceral",
"    </span>",
"    involvement, local complications, and functional impairment. Rapid evolution was prevalent in the florid and disseminated stages (92 and 100 percent, respectively), and less frequent in the infiltrative and maculonodular stages (42 and 21 percent, respectively). Visceral involvement occurred only in patients with stage IIIB and IV disease (1.2 and 24 percent, respectively). Survival for the four groups was not reported.",
"   </p>",
"   <p>",
"    The authors proposed using this classification scheme to select patients with the most aggressive natural history (ie, those with stages IIB, III, and IV disease) for systemic therapy. However, this staging system is not in widespread use. It is based upon subjective rather than objective classification of the extent of disease, and its prognostic value has not been independently validated. Furthermore, its predictive value for response to systemic therapy has not been addressed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the absence of treatments capable of eradicating latent HHV-8 infection, one can question whether any form of Kaposi sarcoma, including Classic Kaposi sarcoma (CKS), can be considered \"curable\". Nonetheless, a number of strategies have been used to manage CKS, with the major therapeutic goals of achieving symptom palliation, alleviating lymphedema, improving function, decreasing the size of cutaneous or visceral lesions, and delaying or preventing disease progression.",
"   </p>",
"   <p>",
"    With relatively few exceptions, the published literature on treatment of CKS consists of retrospective series and case reports. Prospectively designed phase II trials are scarce, usually include relatively few patients, and do not use standardized objective methods to document response. Furthermore, with a single exception [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/25\">",
"     25",
"    </a>",
"    ], there are no prospectively randomized trials that compare different treatments for CKS, making it impossible to identify the \"best\" approach. This is not surprising given the relative scarcity of the disease, the advanced age of many affected individuals, and the frequent presence of comorbidities that may limit treatment options and the ability to participate in clinical trails.",
"   </p>",
"   <p>",
"    Despite these limitations, some general principles have emerged about CKS treatment based on empirical evidence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Observation without specific treatment is an option for patients who have a limited number of asymptomatic lesions that do not impair function, although disease progression eventually occurs in most patients. In a study of 39 patients with asymptomatic lesions who were observed without specific treatment, only 34 percent remained progression-free at two years [",
"      <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Symptoms related to limited lower extremity edema can be alleviated in many patients with elastic compression stockings [",
"      <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When treatment is indicated, there are a variety of local and systemic tumor-directed therapy options, the choice of which depends on the extent, location, and pace of disease.",
"     </li>",
"     <li>",
"      The presence of regional nodal disease does not necessarily influence the choice of local versus systemic treatment. Unless the nodal disease is large and symptomatic (an uncommon scenario), we treat these patients based upon the volume and extent of their local skin disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Local treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;These are treatments directed at specific lesions or groups of lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some cases, if there is a single symptomatic lesion (eg, bleeding or chafing against clothing), excision alone may provide sustained local tumor control [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/18,19,27\">",
"     18,19,27",
"    </a>",
"    ], but new lesions commonly develop at other sites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;All forms of KS, including CKS, are very sensitive to radiotherapy (RT). However, because of the multifocal nature of the disease, the persistence of HHV-8 even with successful local lesion control, and the tendency for new lesions to develop in nonirradiated areas, there is no consensus as to the place of RT in the therapeutic armamentarium (particularly when to choose RT over systemic therapy) or the optimal radiation technique.",
"   </p>",
"   <p>",
"    Several successful strategies have been described [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/18,28-38\">",
"     18,28-38",
"    </a>",
"    ]. High rates of tumor regression are reported using different energy sources (Cobalt-60, low-energy electrons, superficial X-rays) to deliver local (or, occasionally extended-field) RT. There is marked variation in total RT doses (6 to 60 Gy) and in the fractionation regimens, which range from doses of 6 to 12 Gy in a single fraction to larger total doses administered in smaller fractions over several weeks [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/18,28,29,31-35,38\">",
"     18,28,29,31-35,38",
"    </a>",
"    ]. One of the most commonly prescribed regimens is 30 Gy in 15 daily 2 Gy fractions [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although durable local lesion control and symptom relief can be achieved in over 90 percent of cases, most publications do not clearly address the frequency of out-of-field recurrences and the eventual need for additional local or systemic therapy. Treatment of solitary lesions as they arise may require irradiation of numerous adjacent fields and can lead to dosimetric problems at junction points. For this reason, although overall response rates are similar, some authors prefer a strategy of once-weekly total or subtotal skin electron beam therapy (for three to four sessions) over local involved-field radiotherapy, because of the lower out-of-field recurrence rates [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/30\">",
"     30",
"    </a>",
"    ]. One other frequently employed technique is treatment of the involved portion(s) of the feet and lower extremities when extensively involved using a water bath technique, which allows homogeneous radiation of a complex target. In one series using a split course technique delivering 30 Gy in 10 fractions, disappearance of lesions was seen in 89 percent of patients, although limb edema only regressed in 57 percent [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Cryotherapy and laser therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with AIDS-related KS [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/40\">",
"     40",
"    </a>",
"    ], liquid nitrogen cryotherapy is sometimes used (mainly by dermatologists) for local control of small CKS lesions [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. However, the effect is mainly cosmetic, and there is no information on the impact of this form of local therapy on long-term disease control.",
"   </p>",
"   <p>",
"    Laser therapy may also be useful for selected cases [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Intralesional therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intralesional injection of chemotherapy (most often",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    , but sometimes",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ) leads to local regression of cutaneous KS lesions [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. In our experience, such injections, while capable of eradicating injected tumors, can be painful and lead to local scarring. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/37/18009?source=see_link&amp;anchor=H16#H16\">",
"     \"AIDS-related Kaposi sarcoma: Staging and treatment\", section on 'Local symptomatic therapy'",
"    </a>",
"    .) One report has also described a high response rate in single nodular CKS lesions treated with intralesional",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intralesional injection of interferon alfa, alone or in combination with interleukin-2, has also been reported to induce regression of classical KS lesions [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. The studies cited evaluated the effects of twice- or thrice-weekly injections over a period of four to six weeks, which is unlikely to be practical for routine treatment of individuals with multiple cutaneous lesions. &nbsp;",
"   </p>",
"   <p>",
"    Electrochemotherapy uses a small electric current (electroporation, a form of electromotive drug administration) to increase drug delivery into the tumor; this approach has been used primarily with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    .&nbsp;In one series of 23 patients with classical KS treated with this approach, all patients showed tumor regression, which was complete in 65 percent [46].&nbsp;It should be noted, however, that general or spinal anaesthesia was required to administer the treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Topical therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cis-retinoic acid &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/45/25299?source=see_link\">",
"       Alitretinoin",
"      </a>",
"      (9-cis-retinoic acid) gel 0.1 percent is an FDA-approved topical treatment for cutaneous AIDS-associated KS but published experience in CKS is limited. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/37/18009?source=see_link&amp;anchor=H16#H16\">",
"       \"AIDS-related Kaposi sarcoma: Staging and treatment\", section on 'Local symptomatic therapy'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      A single case report of an elderly patient with CKS noted a good local response with partial or complete resolution of multiple treated cutaneous lesions, although the patient continued to develop new lesions in untreated skin [",
"      <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/49\">",
"       49",
"      </a>",
"      ]. Of note, another case report described the failure of alitretinoin gel in a patient with CKS [",
"      <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/59/20406?source=see_link\">",
"       Imiquimod",
"      </a>",
"      &mdash; A prospective clinical trial of topical imiquimod demonstrated an objective response (complete or partial) in 47 percent of 17 patients with non-AIDS-related KS [",
"      <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/51\">",
"       51",
"      </a>",
"      ]. Response was assessed at only one point (36 weeks), and the duration of disease control was not reported. There was an inverse association between lesion area and response. A single case report described complete regression of extensive CKS using topical imiquimod with occlusive dressings [",
"      <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nicotine&nbsp;patches &mdash; Based upon the observation that smoking was associated with a reduced risk of CKS, and the potential effects of nicotine both on immune function and vasoconstriction, a randomized, placebo-controlled trial of dermal nicotine patches was conducted in CKS [",
"      <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/53\">",
"       53",
"      </a>",
"      ]. Treatment was well tolerated, but there were no significant effects on CKS lesions or on HHV-8 antibody titers or DNA levels in PBMCs [",
"      <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/53\">",
"       53",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis?source=see_link&amp;anchor=H12#H12\">",
"       \"Classic Kaposi sarcoma: Epidemiology, risk factors, pathology, and molecular pathogenesis\", section on 'Smoking'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Systemic treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;These are treatments with the potential to cause regression at all disease sites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Widespread, bulky, or rapidly progressive CKS, particularly when it interferes with function or is associated with moderate to severe symptomatic edema or visceral organ involvement, is an indication for systemic chemotherapy. Although no cytotoxic chemotherapeutic agents have been approved in the US or elsewhere specifically for treatment of CKS, a number of drugs approved for treatment of AIDS-associated KS or other neoplasms have activity against CKS either as initial chemotherapy or, in some cases, after failure of prior therapy. These include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"     pegylated liposomal doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    (alone or in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    , oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/18,20,25,54-67\">",
"     18,20,25,54-67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall response rates for all of these drugs or drug combinations have been quite high (60 to over 90 percent), and the treatments are generally well tolerated, even in the elderly population at greatest risk for CKS. Median response durations range from four months to over two years.",
"   </p>",
"   <p>",
"    In the absence of uniform prospectively-defined objective criteria for inclusion or for response and progression, and in the absence of randomized trials, it is difficult to make recommendations for preferred treatments on the basis of response rates, duration of benefit, or adverse effects [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Only one randomized trial has been conducted in which two different systemic therapies were compared [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/25\">",
"     25",
"    </a>",
"    ]. Sixty-five patients with CKS were randomly assigned to oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    (60",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily for three days for the first cycle, four days for the second cycle, and five days for the third cycle, as tolerated, with courses repeated every three weeks) or intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    (3",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly for three weeks, then 6",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks).",
"   </p>",
"   <p>",
"    There were no significant differences between the two treatments with regard to response rate (74 versus 58 percent with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    , respectively), duration of response, or survival (median not reached in either group with a median follow-up of 38 months). Side effects were infrequent and mild in both groups, although alopecia and nausea and vomiting (all grade 1 or 2) were more prominent with etoposide and myelosuppression was more evident with vinblastine (grade 1 in 7, grade 3 in 2).",
"   </p>",
"   <p>",
"    Despite the lack of randomized trials demonstrating superiority, most clinicians consider",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"     pegylated liposomal doxorubicin",
"    </a>",
"    (PLD, a drug approved in the US for AIDS-related KS) to be the first-line therapy of choice unless there is a cardiac contraindication. The benefit of first-line PLD (20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks) was addressed in a retrospective multi-institutional series of 55 patients with CKS [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/20\">",
"     20",
"    </a>",
"    ]. A complete (absence of detectable lesions for at least eight weeks) or major response (&ge;50 percent decrease in the number of measurable lesions, and absence of new cutaneous lesions for at least eight weeks) was noted in 71 percent. The median time to response was four months, and the median response duration was 25 months.",
"   </p>",
"   <p>",
"    The optimal duration of chemotherapy has not been systematically studied. We usually treat with one or two courses beyond a stable maximal response and gradually stretch out the intervals between treatments. If there is no evidence of progression, we attempt to discontinue therapy, and closely monitor, offering retreatment with the same regimen at the time of progression.",
"   </p>",
"   <p>",
"    For patients who do not respond to PLD (or who initially respond but then become refractory to the drug), the choice of a second-line agent (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    alone or in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    , oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    ) must be individualized, taking into account age, comorbidity, and personal preference.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Immunomodulators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recombinant interferon alfa (IFNa) is approved for treatment of AIDS-associated KS in the US. While the mechanism of antitumor action of IFNa in KS is not known, it may involve direct antiproliferative effects, antiviral effects, inhibition of angiogenesis, and modulation of host cellular and humoral immune responses [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/37/18009?source=see_link&amp;anchor=H20#H20\">",
"     \"AIDS-related Kaposi sarcoma: Staging and treatment\", section on 'Other agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is limited experience with this drug in CKS. In a prospectively-designed phase II clinical trial, 16 patients (13 with CKS, three with endemic African KS), nine of whom were refractory to chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiotherapy, were treated with IFNa (5 million units subcutaneously three times a week) for a minimum of six months [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/70\">",
"     70",
"    </a>",
"    ]. Major (complete or partial) tumor regressions were observed in 10 patients, and four other patients showed minor response or stable disease. However, side effects, especially fatigue, low-grade fever, myalgias, and depression, can be prominent.",
"   </p>",
"   <p>",
"    Lower doses of IFNa (1 to 3 million units, five days a week) induced complete regression of CKS in three patients and a partial regression in a fourth [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/71\">",
"     71",
"    </a>",
"    ]. In another small case series however, only one of six CKS patients treated at an IFNa dose of 3 million units, three times a week, showed a major response, while four others showed minor (&lt;50 percent) tumor regression [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Like IFNa,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    has anti-angiogenic and immunomodulatory effects, and the drug is active in AIDS-related KS [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/72\">",
"     72",
"    </a>",
"    ]. Experience with thalidomide is limited in CKS [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. One report noted activity in three patients with CKS who received thalidomide 100 mg daily [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/73\">",
"     73",
"    </a>",
"    ]. Two of the three had a complete clinical response after 12 months of treatment. In the second series, 3 of 11 patients with CKS had a partial response to the same dose of thalidomide [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/74\">",
"     74",
"    </a>",
"    ]. Three patients discontinued drug therapy prematurely due to sensory neuropathy or vertigo. Thalidomide is not an FDA-approved treatment for any form of KS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Investigational therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approaches under investigation for AIDS-associated KS, many of which target angiogenesis, are also being tested against CKS [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. Several phase II protocols studying new approaches are open for patients with either HIV-related or non HIV-related KS [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/78\">",
"     78",
"    </a>",
"    ]. There is no reason to believe a priori that any of these approaches (with the exception of those specifically targeting HIV infection), if proven successful, would not also apply to treatment of CKS.",
"   </p>",
"   <p>",
"    One study attempted to exploit the finding that HIV protease inhibitors exert antiangiogenic and antitumor properties that are distinct from their antiretroviral effects [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/79\">",
"     79",
"    </a>",
"    ]. Sixteen of 28 patients with CKS who were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    were described as having benefits that included a complete response (n = 1), partial response (n = 2), \"improved disease\" (n = 5) and stabilization of progressive disease (n = 8). The authors described an association between a favorable clinical course and higher plasma indinavir levels, reduced levels of basic fibroblast growth factor, lower numbers of circulating endothelial cells (a cell type reported to be increased in CKS [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/80\">",
"     80",
"    </a>",
"    ]), and a reduction in HHV-8 antibody titers.",
"   </p>",
"   <p>",
"    Case reports describing regression of CKS in patients treated with the mTOR inhibitor, rapamycin (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/77,81\">",
"     77,81",
"    </a>",
"    ] suggest that this approach, which has proven effective in some cases of transplant-associated KS, may be more generally applicable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"./kaposi-sarcoma-the-basics?source=see_link\">",
"       \"Patient information: Kaposi sarcoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Classic Kaposi sarcoma (CKS) is a neoplasm characterized by abnormal angiogenesis that requires infection with a human herpes virus, HHV-8, along with other cofactors. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CKS arises most commonly in elderly men of Mediterranean and",
"      <span class=\"nowrap\">",
"       Central/Eastern",
"      </span>",
"      European descent, but it can also occur in younger individuals, in women, and in other geographic areas. (See",
"      <a class=\"medical medical_review\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis?source=see_link&amp;anchor=H2#H2\">",
"       \"Classic Kaposi sarcoma: Epidemiology, risk factors, pathology, and molecular pathogenesis\", section on 'Epidemiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The most common presentation is that of purplish, reddish blue, or dark",
"      <span class=\"nowrap\">",
"       brown/black",
"      </span>",
"      skin lesions (macules, nodules, plaques) on the lower extremities, often with lymphedema. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CKS is frequently described as slow-growing, localized and indolent, but it can become disseminated",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      grow rapidly, and cause significant morbidity and mortality. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of CKS requires a biopsy. Involvement of mucous membranes, lymph nodes, and visceral organs is relatively infrequent; radiographic staging evaluation and endoscopic screening are not routinely indicated in asymptomatic patients. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Extracutaneous involvement'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Radiographic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus on the optimal tumor-directed therapy for different CKS manifestations. Because many active treatments have been described, therapeutic choices are often made based upon the experience and medical discipline of the treating clinician, but also include consideration of patient preferences and comorbid conditions.",
"   </p>",
"   <p>",
"    The following represents our general approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest observation rather than specific treatment for patients who have a limited number of asymptomatic lesions that do not impair function (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Symptoms related to limited lower extremity edema can be alleviated in many patients with elastic compression stockings. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have limited volume disease causing symptoms (eg, bleeding or chafing against clothes) or cosmetic disfigurement, we suggest local treatment rather than observation or systemic chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The choice of modality (radiation therapy, excision, cryotherapy, laser ablation) depends on a number of factors, including the site and extent of the disease involvement as well as clinician and patient preference. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Local treatments'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no consensus as to the indications for systemic therapy. We consider this approach in (but not limited to) the following situations:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Symptomatic visceral or mucosal involvement (although rare)",
"     </li>",
"     <li>",
"      Diffuse symptomatic lesions on multiple body parts that are not easily encompassed in a single or a limited number of radiation fields",
"     </li>",
"     <li>",
"      Extensive nodular disease or diffuse involvement of a large portion of an extremity",
"     </li>",
"     <li>",
"      Bulky disease in a localized area of one limb that cannot be encompassed within a single radiation therapy port",
"     </li>",
"     <li>",
"      Moderate to severe associated lymphedema beyond what can be controlled with elastic stockings",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When there is an indication for chemotherapy we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"       pegylated liposomal doxorubicin",
"      </a>",
"      (PLD) as the first line regimen, in the absence of a cardiac contraindication (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have progressed while receiving PLD or for those who do not respond to PLD, there are several options for second-line therapy in those who retain an adequate performance status. The available options include a single agent taxane, oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      . No one regimen can be recommended over any other. The decision must be individualized, taking into consideration patient age, accompanying comorbidity, and clinician and patient preference.",
"     </li>",
"     <li>",
"      There is a need for prospectively-defined studies that use well-defined response criteria to better define optimal treatment(s) for CKS.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/1\">",
"      Gao SJ, Kingsley L, Hoover DR, et al. Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med 1996; 335:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/2\">",
"      Gao SJ, Kingsley L, Li M, et al. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med 1996; 2:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/3\">",
"      Martin JN, Ganem DE, Osmond DH, et al. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med 1998; 338:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/4\">",
"      Schwartz RA. Kaposi's sarcoma: an update. J Surg Oncol 2004; 87:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/5\">",
"      Mohanna S, Sanchez J, Ferrufino JC, et al. Lymphangioma-like Kaposi's sarcoma: report of four cases and review. J Eur Acad Dermatol Venereol 2006; 20:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/6\">",
"      RONCHESE F, KERN AB. Lymphangioma-like tumors in Kaposi's sarcoma. AMA Arch Derm 1957; 75:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/7\">",
"      Pantanowitz L, Duke WH. Lymphoedematous variants of Kaposi's sarcoma. J Eur Acad Dermatol Venereol 2008; 22:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/8\">",
"      Balachandra B, Tunitsky E, Dawood S, et al. Classic Kaposi's sarcoma presenting first with gastrointestinal tract involvement in a HIV-negative Inuit male--a case report and review of the literature. Pathol Res Pract 2006; 202:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/9\">",
"      Neff R, Kremer S, Voutsinas L, et al. Primary Kaposi's sarcoma of the ileum presenting as massive rectal bleeding. Am J Gastroenterol 1987; 82:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/10\">",
"      Weprin L, Zollinger R, Clausen K, Thomas FB. Kaposi's sarcoma: endoscopic observations of gastric and colon involvement. J Clin Gastroenterol 1982; 4:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/11\">",
"      Stratigos JD, Potouridou I, Katoulis AC, et al. Classic Kaposi's sarcoma in Greece: a clinico-epidemiological profile. Int J Dermatol 1997; 36:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/12\">",
"      Jaimovich L, Calb I, Kaminsky A. Kaposi's sarcoma of the conjunctiva. J Am Acad Dermatol 1986; 14:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/13\">",
"      Cottoni F, Masala MV, Piras P, et al. Mucosal involvement in classic Kaposi's sarcoma. Br J Dermatol 2003; 148:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/14\">",
"      Kolios G, Kaloterakis A, Filiotou A, et al. Gastroscopic findings in Mediterranean Kaposi's sarcoma (non-AIDS). Gastrointest Endosc 1995; 42:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/15\">",
"      Caponetti G, Dezube BJ, Restrepo CS, Pantanowitz L. Kaposi sarcoma of the musculoskeletal system: a review of 66 patients. Cancer 2007; 109:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/16\">",
"      Bordelon TR, Burton GV, Grafton WD, Mills GM. Kaposi's sarcoma involvement of the bone marrow. Am J Med Sci 1990; 300:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/17\">",
"      Coll J, Pedro-Botet J, Pallas JO, et al. Classic Kaposi's sarcoma with pulmonary involvement in an HIV-negative woman. Clin Exp Dermatol 1995; 20:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/18\">",
"      Brenner B, Rakowsky E, Katz A, et al. Tailoring treatment for classical Kaposi's sarcoma: comprehensive clinical guidelines. Int J Oncol 1999; 14:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/19\">",
"      Zurrida S, Bartoli C, Nol&eacute; F, et al. Classic Kaposi's sarcoma: a review of 90 cases. J Dermatol 1992; 19:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/20\">",
"      Di Lorenzo G, Kreuter A, Di Trolio R, et al. Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi's sarcoma: a multicenter study. J Invest Dermatol 2008; 128:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/21\">",
"      Hiatt KM, Nelson AM, Lichy JH, Fanburg-Smith JC. Classic Kaposi Sarcoma in the United States over the last two decades: a clinicopathologic and molecular study of 438 non-HIV-related Kaposi Sarcoma patients with comparison to HIV-related Kaposi Sarcoma. Mod Pathol 2008; 21:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/22\">",
"      Potouridou I, Katsambas A, Pantazi V, et al. Classic Kaposi's sarcoma in two young heterosexual men. J Eur Acad Dermatol Venereol 1998; 10:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/23\">",
"      Kaposi M. Idiopathic multiple pigmented sarcoma of the skin. [English translation from Archiv F&uuml;r Dermatolgie Und Syphillis 1872; 4:265-273]. CA Cancer J Clin 1982; 32:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/24\">",
"      Brambilla L, Boneschi V, Taglioni M, Ferrucci S. Staging of classic Kaposi's sarcoma: a useful tool for therapeutic choices. Eur J Dermatol 2003; 13:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/25\">",
"      Brambilla L, Labianca R, Boneschi V, et al. Mediterranean Kaposi's sarcoma in the elderly. A randomized study of oral etoposide versus vinblastine. Cancer 1994; 74:2873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/26\">",
"      Brambilla L, Tourlaki A, Ferrucci S, et al. Treatment of classic Kaposi's sarcoma-associated lymphedema with elastic stockings. J Dermatol 2006; 33:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/27\">",
"      Weintraub CM, Skudowitz RB. Excision of 1,674 classic Kaposi's sarcomas. S Afr J Surg 2002; 40:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/28\">",
"      Tombolini V, Osti MF, Bonanni A, et al. Radiotherapy in classic Kaposi's sarcoma (CKS): experience of the Institute of Radiology of University \"La Sapienza\" of Rome. Anticancer Res 1999; 19:4539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/29\">",
"      Cooper JS, Sacco J, Newall J. The duration of local control of classic (non-AIDS-associated) Kaposi's sarcoma by radiotherapy. J Am Acad Dermatol 1988; 19:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/30\">",
"      Nisce LZ, Safai B, Poussin-Rosillo H. Once weekly total and subtotal skin electron beam therapy for Kaposi's sarcoma. Cancer 1981; 47:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/31\">",
"      Stein ME, Lakier R, Spencer D, et al. Radiation therapy for non-AIDS associated (classic and endemic African) and epidemic Kaposi's sarcoma. Int J Radiat Oncol Biol Phys 1994; 28:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/32\">",
"      Huang KM, Hsu CH, Cheng JC, et al. Radiotherapy of classic Kaposi's sarcoma in Taiwan, an area where classic Kaposi's sarcoma is not prevalent. Anticancer Res 2006; 26:4659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/33\">",
"      Chang LF, Reddy S, Shidnia H. Comparison of radiation therapy of classic and epidemic Kaposi's sarcoma. Am J Clin Oncol 1992; 15:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/34\">",
"      Caccialanza M, Marca S, Piccinno R, Eulisse G. Radiotherapy of classic and human immunodeficiency virus-related Kaposi's sarcoma: results in 1482 lesions. J Eur Acad Dermatol Venereol 2008; 22:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/35\">",
"      Yildiz F, Ozyar E, Uzal D, et al. Kaposi's sarcoma: the efficacy of a single fraction of 800 cGy. Dermatology 1997; 195:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/36\">",
"      Hauerstock D, Gerstein W, Vuong T. Results of radiation therapy for treatment of classic Kaposi sarcoma. J Cutan Med Surg 2009; 13:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/37\">",
"      Kirova YM, Belembaogo E, Frikha H, et al. Radiotherapy in the management of epidemic Kaposi's sarcoma: a retrospective study of 643 cases. Radiother Oncol 1998; 46:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/38\">",
"      Hamilton CR, Cummings BJ, Harwood AR. Radiotherapy of Kaposi's sarcoma. Int J Radiat Oncol Biol Phys 1986; 12:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/39\">",
"      Weshler Z, Loewinger E, Loewenthal E, et al. Megavoltage radiotherapy using water bolus in the treatment of Kaposi's sarcoma. Int J Radiat Oncol Biol Phys 1986; 12:2029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/40\">",
"      Tappero JW, Berger TG, Kaplan LD, et al. Cryotherapy for cutaneous Kaposi's sarcoma (KS) associated with acquired immune deficiency syndrome (AIDS): a phase II trial. J Acquir Immune Defic Syndr 1991; 4:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/41\">",
"      Von Roenn JH, Cianfrocca M. Treatment of Kaposi's sarcoma. Cancer Treat Res 2001; 104:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/42\">",
"      Webster GF. Local therapy for mucocutaneous Kaposi's sarcoma in patients with acquired immunodeficiency syndrome. Dermatol Surg 1995; 21:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/43\">",
"      Chun YS, Chang SN, Park WH. A case of classical Kaposi's sarcoma of the penis showing a good response to high-energy pulsed carbon dioxide laser therapy. J Dermatol 1999; 26:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/44\">",
"      Marchell N, Alster TS. Successful treatment of cutaneous Kaposi's sarcoma by the 585-nm pulsed dye laser. Dermatol Surg 1997; 23:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/45\">",
"      Odom RB, Goette DK. Treatment of cutaneous Kaposi's sarcoma with intralesional vincristine. Arch Dermatol 1978; 114:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/46\">",
"      Brambilla L, Bellinvia M, Tourlaki A, et al. Intralesional vincristine as first-line therapy for nodular lesions in classic Kaposi sarcoma: a prospective study in 151 patients. Br J Dermatol 2010; 162:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/47\">",
"      Ghyka G, Alecu M, Halalau F, Coman G. Intralesional human leukocyte interferon treatment alone or associated with IL-2 in non-AIDS related Kaposi's sarcoma. J Dermatol 1992; 19:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/48\">",
"      Trattner A, Reizis Z, David M, et al. The therapeutic effect of intralesional interferon in classical Kaposi's sarcoma. Br J Dermatol 1993; 129:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/49\">",
"      Morganroth GS. Topical 0.1% alitretinoin gel for classic Kaposi sarcoma. Arch Dermatol 2002; 138:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/50\">",
"      Rongioletti F, Zaccaria E, Viglizzo G. Failure of topical 0.1% alitretinoin gel for classic Kaposi sarcoma: first European experience. Br J Dermatol 2006; 155:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/51\">",
"      C&eacute;lestin Schartz NE, Chevret S, Paz C, et al. Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients. J Am Acad Dermatol 2008; 58:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/52\">",
"      Goiriz R, R&iacute;os-Buceta L, De Arriba AG, et al. Treatment of classic Kaposi's sarcoma with topical imiquimod. Dermatol Surg 2009; 35:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/53\">",
"      Goedert JJ, Scoppio BM, Pfeiffer R, et al. Treatment of classic Kaposi sarcoma with a nicotine dermal patch: a phase II clinical trial. J Eur Acad Dermatol Venereol 2008; 22:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/54\">",
"      Casti&ntilde;eiras I, Almagro M, Rodr&iacute;guez-Lozano J, et al. Disseminated classic Kaposi's sarcoma. Two cases with excellent response to pegylated liposomal doxorubicin. J Dermatolog Treat 2006; 17:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/55\">",
"      Di Lorenzo G, Di Trolio R, Montesarchio V, et al. Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma: a retrospective study. Cancer 2008; 112:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/56\">",
"      Kreuter A, Rasokat H, Klouche M, et al. Liposomal pegylated doxorubicin versus low-dose recombinant interferon Alfa-2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers. Cancer Invest 2005; 23:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/57\">",
"      Potouridou I, Korfitis C, Ioannidou D, et al. Low to moderate cumulative doses of pegylated liposomal doxorubicin in the treatment of classic Kaposi sarcoma in elderly patients with comorbidities. Br J Dermatol 2008; 158:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/58\">",
"      Brambilla L, Labianca R, Ferrucci SM, et al. Treatment of classical Kaposi's sarcoma with gemcitabine. Dermatology 2001; 202:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/59\">",
"      Brambilla L, Boneschi V, Fossati S, et al. Oral etoposide for Kaposi's Mediterranean sarcoma. Dermatologica 1988; 177:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/60\">",
"      Brambilla L, Miedico A, Ferrucci S, et al. Combination of vinblastine and bleomycin as first line therapy in advanced classic Kaposi's sarcoma. J Eur Acad Dermatol Venereol 2006; 20:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/61\">",
"      Brambilla L, Romanelli A, Bellinvia M, et al. Weekly paclitaxel for advanced aggressive classic Kaposi sarcoma: experience in 17 cases. Br J Dermatol 2008; 158:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/62\">",
"      Chao SC, Lee JY, Tsao CJ. Treatment of classical type Kaposi's sarcoma with paclitaxel. Anticancer Res 2001; 21:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/63\">",
"      Fardet L, Stoebner PE, Bachelez H, et al. Treatment with taxanes of refractory or life-threatening Kaposi sarcoma not associated with human immunodeficiency virus infection. Cancer 2006; 106:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/64\">",
"      Satoh H, Ishikawa H, Yamashita YT, et al. Pleural to serum CEA ratio in lung adenocarcinoma. Clin Oncol (R Coll Radiol) 2002; 14:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/65\">",
"      Zustovich F, Lombardi G, Pastorelli D. Important role of gemcitabine in the treatment of classic Kaposi's sarcoma. Tumori 2009; 95:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/66\">",
"      Zidan J, Robenstein W, Abzah A, Taman S. Treatment of Kaposi's sarcoma with vinblastine in patients with disseminated dermal disease. Isr Med Assoc J 2001; 3:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/67\">",
"      Brambilla L, Labianca R, Fossati S, et al. Vinorelbine: an active drug in Mediterranean Kaposi&rsquo;s sarcoma. Eur J Dermatol 1995; 5:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/68\">",
"      R&eacute;gnier-Rosencher E, Guillot B, Dupin N. Treatments for classic Kaposi sarcoma: a systematic review of the literature. J Am Acad Dermatol 2013; 68:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/69\">",
"      Krown SE. AIDS-associated Kaposi's sarcoma: is there still a role for interferon alfa? Cytokine Growth Factor Rev 2007; 18:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/70\">",
"      Costa da Cunha CS, Lebbe C, Rybojad M, et al. Long-term follow-up of non-HIV Kaposi's sarcoma treated with low-dose recombinant interferon alfa-2b. Arch Dermatol 1996; 132:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/71\">",
"      Tur E, Brenner S, Michalevicz R. Low dose recombinant interferon alfa treatment for classic Kaposi's sarcoma. Arch Dermatol 1993; 129:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/72\">",
"      Krown SE. Management of Kaposi sarcoma: the role of interferon and thalidomide. Curr Opin Oncol 2001; 13:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/73\">",
"      Rubegni P, Sbano P, De Aloe G, et al. Thalidomide in the treatment of Kaposi's sarcoma. Dermatology 2007; 215:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/74\">",
"      Ben M'barek L, Fardet L, Mebazaa A, et al. A retrospective analysis of thalidomide therapy in non-HIV-related Kaposi's sarcoma. Dermatology 2007; 215:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/75\">",
"      Dittmer DP, Krown SE. Targeted therapy for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus. Curr Opin Oncol 2007; 19:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/76\">",
"      Ganjoo K, Jacobs C. Antiangiogenesis agents in the treatment of soft tissue sarcomas. Cancer 2010; 116:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/77\">",
"      Guenova E, Metzler G, Hoetzenecker W, et al. Classic Mediterranean Kaposi's sarcoma regression with sirolimus treatment. Arch Dermatol 2008; 144:692.",
"     </a>",
"    </li>",
"    <li>",
"     Active protocols for treatment of Kaposi's sarcoma available online. www.cancer.gov/clinicaltrials/search (Accessed on February 29, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/79\">",
"      Monini P, Sgadari C, Grosso MG, et al. Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir. AIDS 2009; 23:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/80\">",
"      Taddeo A, Presicce P, Brambilla L, et al. Circulating endothelial progenitor cells are increased in patients with classic Kaposi's sarcoma. J Invest Dermatol 2008; 128:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment/abstract/81\">",
"      Merimsky O, Jiveliouk I, Sagi-Eisenberg R. Targeting mTOR in HIV-Negative Classic Kaposi's Sarcoma. Sarcoma 2008; 2008:825093.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7729 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-E2D9733EE5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_8_38025=[""].join("\n");
var outline_f37_8_38025=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Skin lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Extracutaneous involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Natural history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS AND STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Radiographic evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Local treatments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Cryotherapy and laser therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Intralesional therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Topical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Systemic treatments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Immunomodulators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Investigational therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7729\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7729|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/21/35152\" title=\"picture 1A\">",
"      Classic Kaposi sarcoma - patches and plaques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/27/18866\" title=\"picture 1B\">",
"      Classic Kaposi sarcoma - papules and plaques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/37/16979\" title=\"picture 1C\">",
"      Classic Kaposi sarcoma - nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7729|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/16/18700\" title=\"table 1\">",
"      Epid clin types KS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/52/12103?source=related_link\">",
"      AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/37/18009?source=related_link\">",
"      AIDS-related Kaposi sarcoma: Staging and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis?source=related_link\">",
"      Classic Kaposi sarcoma: Epidemiology, risk factors, pathology, and molecular pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/11/12469?source=related_link\">",
"      Clinical features and diagnosis of sporotrichosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36583?source=related_link\">",
"      Clinical features, diagnosis, and treatment of Bartonella quintana infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/52/1866?source=related_link\">",
"      Clinical manifestations and diagnosis of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/23/34170?source=related_link\">",
"      Development of malignancy following solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24089?source=related_link\">",
"      Epidemiology of nontuberculous mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"./kaposi-sarcoma-the-basics?source=related_link\">",
"      Patient information: Kaposi sarcoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/1/33817?source=related_link\">",
"      Prevention and treatment of lymphedema",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_8_38026="Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania";
var content_f37_8_38026=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/8/38026/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/8/38026/contributors\">",
"     Jeffrey Stovall, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/8/38026/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/8/38026/contributors\">",
"     Paul Keck, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/8/38026/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/8/38026/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/8/38026/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bipolar disorder is marked by episodes of mania (",
"    <a class=\"graphic graphic_table graphicRef81976 \" href=\"mobipreview.htm?3/53/3932\">",
"     table 1",
"    </a>",
"    ) and hypomania (",
"    <a class=\"graphic graphic_table graphicRef70757 \" href=\"mobipreview.htm?22/39/23164\">",
"     table 2",
"    </a>",
"    ), as well as mixed episodes of concurrent major depression (",
"    <a class=\"graphic graphic_table graphicRef70852 \" href=\"mobipreview.htm?17/21/17756\">",
"     table 3",
"    </a>",
"    ) and mania or hypomania [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/1\">",
"     1",
"    </a>",
"    ]. Despite clinical differences among manic, hypomanic, and mixed episodes, for the purpose of treatment they are considered to be similar and thus treated with the same medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews treatment of acute mania, mixed episodes, and hypomania. Treatment of acute bipolar depression and maintenance treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44088?source=see_link\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=see_link\">",
"     \"Bipolar disorder in adults: Maintenance treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259896878\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bipolar disorder is a mood disorder that is characterized by periods of pathologic mood elevation (mania or hypomania) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients with bipolar I disorder experience manic episodes (",
"    <a class=\"graphic graphic_table graphicRef81976 \" href=\"mobipreview.htm?3/53/3932\">",
"     table 1",
"    </a>",
"    ) or mixed episodes (major depression concurrent with mania), and nearly always experience major depressive episodes (",
"    <a class=\"graphic graphic_table graphicRef70852 \" href=\"mobipreview.htm?17/21/17756\">",
"     table 3",
"    </a>",
"    ). The clinical course of bipolar II disorder is characterized by at least one episode of hypomania (",
"    <a class=\"graphic graphic_table graphicRef70757 \" href=\"mobipreview.htm?22/39/23164\">",
"     table 2",
"    </a>",
"    ), and one or more major depressive episodes. Despite clinical differences among manic, hypomanic, and mixed episodes (eg, hypomania is less severe than mania), for the purpose of treatment they are considered to be similar and thus treated with the same medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The clinical features and diagnosis of bipolar disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=see_link&amp;anchor=H4#H4\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\", section on 'Clinical manifestations and diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pharmacotherapy for mania or mixed episodes depends upon their severity. Although there are no established criteria that demarcate severe episodes from mild to moderate illness, we classify episodes as severe if they include any of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Suicidal ideation or behavior",
"     </li>",
"     <li>",
"      Homicidal ideation or behavior",
"     </li>",
"     <li>",
"      Aggressive behavior",
"     </li>",
"     <li>",
"      Psychotic features (ie, delusions or hallucinations)",
"     </li>",
"     <li>",
"      Poor judgement that places the patient or others at imminent risk of being harmed &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H324798\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite clinical differences among manic, hypomanic, and mixed episodes (eg, hypomania is less severe than mania), for the purpose of treatment they are considered to be similar and thus treated with the same medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/2-5\">",
"     2-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H324989\">",
"    <span class=\"h2\">",
"     Goal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of treating acute manic, hypomanic, and mixed episodes is remission, which is defined as resolution of the mood symptoms or improvement to the point that only one or two symptoms of mild intensity persist. If psychotic features (delusions or hallucinations) are also present, resolution of the psychosis is required for remission. For patients who do not achieve remission, a reasonable goal is response, which is defined as stabilization of the patient&rsquo;s safety and substantial improvement in the number, intensity, and frequency of mood (and psychotic) symptoms. A standardized rating scale, such as the Young Mania Rating Scale, can be used to quantify response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/6\">",
"     6",
"    </a>",
"    ], although this is not standard clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of mood elevated syndromes (ie, manic, hypomanic, and mixed episodes) begins with an initial psychiatric history and mental status examination that emphasizes symptoms of the mood episode, particularly risk of suicide, aggressiveness, and violence to others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/2,3,7\">",
"     2,3,7",
"    </a>",
"    ]. The assessment should also pursue comorbid disorders (eg, substance use disorders) that require treatment. The evaluation includes a general medical history, physical examination, and focused laboratory studies to establish whether the mood syndrome is due to the direct physiologic effects of a general medical condition, and to rule out any contraindications to treatment (eg, renal impairment and use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , or hepatic disease and use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    ). Additional information about the assessment for bipolar disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=see_link&amp;anchor=H15#H15\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who suffer mania, hypomania, or a mixed episode during maintenance pharmacotherapy should be assessed for adherence to treatment and are initially treated by optimizing medication doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/2,8,9\">",
"     2,8,9",
"    </a>",
"    ]. This includes ensuring serum concentrations are in the therapeutic range for medications such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    , as well as increasing the dose to achieve a higher serum level within the therapeutic range, provided that side effects do not intervene. For medications that do not have an established therapeutic serum concentration, such as antipsychotics, the dose can be increased within the target dose range. &nbsp;",
"   </p>",
"   <p>",
"    Substances may cause or exacerbate a mood elevated syndrome. Thus, antidepressants should be abruptly discontinued, and patients should discontinue drugs of abuse and reduce or eliminate their use of alcohol, caffeine, and nicotine.",
"   </p>",
"   <p>",
"    Evidence for the efficacy of treating mood elevated syndromes is primarily based upon randomized trials with bipolar I manic patients, although the majority of trials included some patients with mixed episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Even though bipolar II disorder is more prevalent than bipolar I disorder, relatively little research has focused specifically on treating hypomania [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Many randomized trials either exclude patients with bipolar II disorder or lump them together with bipolar I patients in the analyses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H226715056\">",
"    <span class=\"h3\">",
"     Setting and monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment setting for manic, hypomanic, or mixed episode patients depends upon the severity of symptoms, comorbid psychopathology (eg, substance use disorder), level of psychosocial functioning, and available support. Hospitalization may be required for managing the patient&rsquo;s safety as well as symptoms such as suicidal ideation with a specific plan and intent, delusions or hallucinations, and poor judgment that poses an imminent risk to the patient and others. Moderately ill patients can be treated in a partial hospital (day) program, including patients with suicidality that does not pose an imminent risk (eg, fleeting thoughts of killing oneself, vague or nonexistent plans, and no intent). An outpatient clinic may be suitable for less acutely ill patients (eg, thoughts that family members would be better off if the patient was dead, with no plan or intent to commit suicide).",
"   </p>",
"   <p>",
"    The frequency of assessment generally ranges from daily to monthly, depending upon the severity of persistent symptoms. Hospitalized patients are monitored daily, and patients with active suicidal ideation, a specific plan, and intent to kill themselves may require constant observation. Outpatients who have responded less than 50 percent are generally seen weekly; those who have responded more than 50 percent may be seen every two to four weeks until they remit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259902796\">",
"    <span class=\"h3\">",
"     Medication classes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon randomized trials, drug classes commonly used to treat acute mania, mixed episodes, or hypomania include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"     </li>",
"     <li>",
"      Anticonvulsants",
"     </li>",
"     <li>",
"      Antipsychotics",
"     </li>",
"     <li>",
"      Benzodiazepines",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mainstays of treatment are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , anticonvulsants, and antipsychotics used in combination pharmacotherapy (eg, lithium plus an antipsychotic) or as monotherapy, depending upon the severity of symptoms. Benzodiazepines are primarily used as adjunctive treatment for insomnia, agitation, or anxiety. Treatment of insomnia, agitation, and anxiety are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/62/13290?source=see_link\">",
"     \"Treatment of insomnia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/22/25962?source=see_link\">",
"     \"Assessment and management of the acutely agitated or violent adult\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/38/2665?source=see_link\">",
"     \"Pharmacotherapy for generalized anxiety disorder\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259901057\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although it is not established how long clinicians should wait to assess the benefit of a medication regimen, it is reasonable to allow up to two weeks for a treatment trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/4\">",
"     4",
"    </a>",
"    ]. Most randomized trials last three weeks, and the superior efficacy of active drugs compared with placebo generally begins to manifest within one week.",
"   </p>",
"   <p>",
"    In a post hoc analysis of a randomized trial that treated manic or mixed episode patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    , improvement at week one was evaluated as a predictor of either remission or response (improvement from baseline on the mania rating scale &ge; 50 percent) at week three [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/14\">",
"     14",
"    </a>",
"    ]. Among 234 patients with improvement &ge; 25 percent at week one, 52 percent remitted and 71 percent responded at week three. Conversely, of the 40 patients with &lt;25 percent improvement at week one, 5 percent remitted and 25 percent responded at week three.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259901050\">",
"    <span class=\"h3\">",
"     Predictors of response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subgroups of manic or mixed episode patients who respond more favorably to pharmacotherapy have not been identified. One study involving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    found that response (improvement from baseline on the mania rating scale &ge; 50 percent) was comparable for manic and mixed episodes, as well as psychotic and nonpsychotic episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/15\">",
"     15",
"    </a>",
"    ]. Response was also independent of rapid cycling (four or more mood episodes in the past 12 months), lifetime number of mood episodes, and history of lifetime comorbid substance use disorder.",
"   </p>",
"   <p>",
"    It is not clear if subgroups of manic or mixed episode patients respond preferentially to a specific drug. Some studies have found that patients with mixed episodes or a greater lifetime number of mood episodes did better with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/12,16-18\">",
"     12,16-18",
"    </a>",
"    ], and that improvement of rapid cycling was superior with valproate or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    than lithium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7954915\">",
"    <span class=\"h2\">",
"     Severe manic and mixed episodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe manic or mixed episodes are characterized by suicidal or homicidal ideation or behavior, aggressiveness, psychotic features (ie, delusions or hallucinations), and poor judgement that places the patient or others at imminent risk of being harmed. Severely ill patients generally require hospitalization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2269895045\">",
"    <span class=\"h3\">",
"     First line medication combinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severely ill patients with acute mania or mixed episodes typically require treatment with a medication combination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/2,4,19\">",
"     2,4,19",
"    </a>",
"    ]. We suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    plus an antipsychotic; however,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    plus an antipsychotic is a reasonable alternative. We generally combine lithium or valproate with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    (or another first-generation antipsychotic),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    . In addition, we generally avoid using adjunctive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/20\">",
"     20",
"    </a>",
"    ]. No head-to-head trials have compared antipsychotics in combination with lithium or valproate. Thus, the choice between lithium and valproate, and the choice of an antipsychotic is based upon other factors, including past response to medications, side effect profiles, comorbid general medical conditions, potential for drug-drug interactions, patient preference, and cost.",
"   </p>",
"   <p>",
"    Evidence for the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    plus an antipsychotic includes a review of 20 randomized trials, which estimated that the rate of response (improvement from baseline on the mania rating scale &ge; 50 percent) with lithium or valproate plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    was 20 percent higher compared with lithium or valproate alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, time to response was significantly shorter. Other evidence supporting lithium or valproate plus an antipsychotic includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of 8 randomized trials (1124 manic or mixed episode patients) compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      with placebo as adjunctive treatment for patients who did not respond to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      monotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/22\">",
"       22",
"      </a>",
"      ]. Improvement was significantly greater in patients who received an adjunctive antipsychotic.",
"     </li>",
"     <li>",
"      Two other meta-analyses of 6 randomized trials (1396 manic or mixed episode patients) compared second generation antipsychotics (including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      ) with placebo as adjunctive treatment for patients who did not respond to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      monotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/11,23\">",
"       11,23",
"      </a>",
"      ]. In both studies, improvement was significantly greater with the antipsychotic than placebo. In addition, dropout due to adverse events was comparable for the two groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/11\">",
"       11",
"      </a>",
"      ]. However, adjunctive antipsychotics caused significantly greater weight gain, somnolence, and extrapyramidal symptoms. &nbsp;",
"     </li>",
"     <li>",
"      A subsequent randomized trial compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"       aripiprazole",
"      </a>",
"      with placebo as add-on treatment to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      in 377 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/24\">",
"       24",
"      </a>",
"      ]. Remission occurred in significantly more patients who received aripiprazole compared with placebo (66 versus 51 percent). However, aripiprazole caused significantly higher rates of akathisia (19 versus 5 percent). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Combination pharmacotherapy for severe manic or mixed episodes is endorsed by several treatment guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/2,4,19\">",
"     2,4,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    or divalproex is not efficacious, based upon two randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/11,20\">",
"     11,20",
"    </a>",
"    ]. As an example, a three week trial assigned 656 patients with manic or mixed episodes who had not responded to either lithium or divalproex to receive adjunctive treatment twice per day with ziprasidone 20 to 40 mg, ziprasidone 60 to 80 mg, or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/20\">",
"     20",
"    </a>",
"    ]. Neither high dose nor low dose ziprasidone provided any benefit.",
"   </p>",
"   <p>",
"    In addition, we generally avoid combining",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    with an antipsychotic, based upon randomized trials that found this combination is no more efficacious than carbamazepine alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Carbamazepine induces hepatic enzymes that metabolize antipsychotics, and in one trial lowered the antipsychotic blood level by 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When prescribing a medication combination, both drugs are started and titrated up simultaneously. The doses and side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    , and antipsychotics are discussed elsewhere in this topic. (See",
"    <a class=\"local\" href=\"#H244584\">",
"     'Medication doses and side effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Specific medication interactions that can occur may be determined using the drug interactions tool (Lexi-Interact Online) included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on Drug interactions.",
"   </p>",
"   <p>",
"    Patients who cannot tolerate combination pharmacotherapy are treated with monotherapy. (See",
"    <a class=\"local\" href=\"#H991964\">",
"     'First line monotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7956384\">",
"    <span class=\"h3\">",
"     Resistant patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;A severe manic or mixed episode that does not respond to one medication combination should be treated with a second medication combination. Generally,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    is switched to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    or vice versa. As an example, for patients who do not respond to lithium plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    within two weeks of reaching target doses, we suggest tapering and discontinuing lithium at the same time that valproate is started and titrated up. Lithium is generally tapered over one week by the same amount for each dose decrease (eg, lithium 1800 mg per day is decreased by 600 mg per day, every one to two days). The dose and side effects of lithium and valproate are discussed separately. (See",
"    <a class=\"local\" href=\"#H1829248939\">",
"     'Lithium'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1829256415\">",
"     'Anticonvulsants'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Conversely, for patients who do not respond to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    within two weeks of reaching target doses, we suggest tapering and discontinuing valproate at the same time that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    is started and titrated up. Valproate is generally tapered over one week by the same amount for each dose decrease (eg, valproate 2000 mg per day is decreased by 500 mg per day, every one to two days).",
"   </p>",
"   <p>",
"    For patients who do not respond to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    plus an antipsychotic or to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    plus the same antipsychotic, we suggest starting a third medication combination involving lithium or valproate plus an antipsychotic. The choice between lithium and valproate is based upon efficacy and tolerability in the two prior trials. In addition, the antipsychotic used in the two prior trials is discontinued and a new one chosen from amongst",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    (or another first-generation antipsychotic),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    . No head-to-head trials have compared antipsychotics in combination with lithium or valproate; thus, the choice of an antipsychotic is based upon other factors, including past response to medications, side effect profiles, comorbid general medical conditions, potential for drug-drug interactions, patient preference, and cost.",
"   </p>",
"   <p>",
"    The antipsychotic is generally tapered over one week by the same amount for each dose decrease (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    10 mg per day is decreased by 5 mg per day, every one to two days), and at the same time, the other antipsychotic is started and titrated up. The dose and side effects of antipsychotics are discussed separately. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Antipsychotics'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7956632\">",
"    <span class=\"h3\">",
"     Refractory patients",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7956662\">",
"    <span class=\"h4\">",
"     Electroconvulsive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest electroconvulsive therapy (ECT) for refractory patients whose manic or mixed episode does not respond to four to six medication combinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/4,27,28\">",
"     4,27,28",
"    </a>",
"    ]. In one controlled trial of 30 manic patients, improvement occurred in significantly more patients who received ECT plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    compared with patients who received simulated ECT plus chlorpromazine (80 versus 7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ECT is generally safe and there are no absolute contraindications, even in patients whose general medical status is compromised [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/30\">",
"     30",
"    </a>",
"    ]. However, safety concerns regarding ECT necessitate preprocedure medical consultation. Adverse effects include cardiopulmonary events, aspiration pneumonia, fractures, dental and tongue injuries, headache, nausea, and cognitive impairment. Medical consultation prior to ECT is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21145?source=see_link\">",
"     \"Medical consultation for electroconvulsive therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Electrode placement and other aspects of ECT technique for treating geriatric bipolar disorder have not been standardized. Thus, ECT is typically administered with the same technique used for other indications and is generally given three times per week on alternating days. Most patients, regardless of indication, remit with 6 to 12 treatments, but some patients may require 20 or more. Additional information about ECT is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/21/41305?source=see_link\">",
"     \"Overview of electroconvulsive therapy (ECT) for adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13128?source=see_link\">",
"     \"Technique for performing electroconvulsive therapy (ECT) in adults\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H326320\">",
"    <span class=\"h4\">",
"     Other medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with refractory manic or mixed episodes who decline ECT, do not remit with it, or have no access to it, and who do not respond to medication combinations involving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    (or another first-generation antipsychotic),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    , we suggest pharmacotherapy with lithium or valproate plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/56/2951?source=see_link\">",
"     asenapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/43/44728?source=see_link\">",
"     paliperidone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/31-36\">",
"     31-36",
"    </a>",
"    ]. Patients unresponsive to lithium or valproate plus asenapine, clozapine, or paliperidone may possibly benefit from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    plus lithium,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    monotherapy, and tamoxifen plus lithium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/37-41\">",
"     37-41",
"    </a>",
"    ]. No head-to-head trials have compared these other medication options. Thus, the choice is based upon other factors, including past response to medications, side effect profiles, comorbid general medical conditions, potential for drug-drug interactions, patient preference, and cost.",
"   </p>",
"   <p>",
"    In randomized trials with 977 manic or mixed episode patients,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/56/2951?source=see_link\">",
"     asenapine",
"    </a>",
"    5 to 10 mg two times per day was more efficacious than placebo, but much less efficacious than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    5 to 20 mg once per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Common side effects of asenapine include sedation, fatigue, dizziness, extrapyramidal symptoms, vomiting, dry mouth, and weight gain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Additional information about asenapine is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Limited evidence suggests that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    may ameliorate refractory manic or mixed episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/31,34,35\">",
"     31,34,35",
"    </a>",
"    ]. Clozapine is started at a dose of 12.5 or 25 mg at bedtime, and then increased by 25 mg per day every two days as tolerated, to a target dose of 150 to 450 mg two times per day. However, clozapine can cause agranulocytosis and other blood dyscrasias, and clinicians must monitor complete blood counts every one or two weeks. Clozapine is also associated with the metabolic syndrome. Thus, patients taking clozapine should be regularly monitored for weight, waist circumference, blood pressure, and serum glucose and lipids. Additional information about clozapine is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=see_link&amp;anchor=H76524735#H76524735\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\", section on 'Clozapine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/43/44728?source=see_link\">",
"     Paliperidone",
"    </a>",
"    has demonstrated inconsistent benefits in patients with acute manic and mixed episodes. A randomized trial compared paliperidone (flexibly dosed 3 to 12 mg per day) with placebo in 268 patients with a manic or mixed episode, and found that remission occurred in significantly more patients who received paliperidone than placebo (52 versus 29 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/36\">",
"     36",
"    </a>",
"    ]. However, a second randomized trial found remission did not differ significantly between the groups who received fixed doses of paliperidone 3 mg, 6 mg, or 12 mg, and the group that received placebo (37 or 42 or 45 versus 37 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/42\">",
"     42",
"    </a>",
"    ]. A third randomized trial found that among patients with an inadequate response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    monotherapy, there was no significant difference between adjunctive paliperidone and adjunctive placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/43\">",
"     43",
"    </a>",
"    ]. The most common adverse events with paliperidone are headache, somnolence, dizziness, akathisia, hypertonia, and dyspepsia. Additional information about paliperidone is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=see_link&amp;anchor=H76524714#H76524714\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\", section on 'Paliperidone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     Allopurinol",
"    </a>",
"    , which is typically used to prevent attacks of gouty arthritis and nephropathy, has been studied as an option for treating mania [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/44\">",
"     44",
"    </a>",
"    ], based upon observations that adenosine, a purine compound and neuromodulator, is metabolized to uric acid, and that increased uric acid turnover is related to remission of mania [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/37,45\">",
"     37,45",
"    </a>",
"    ]. In a randomized trial with 180 manic inpatients, remission occurred in significantly more patients who received allopurinol (600",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    plus lithium or placebo plus lithium (64 versus 42 and 39 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    is a centrally active protein kinase C inhibitor that has demonstrated efficacy for treating manic and mixed episodes in several small randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. The largest compared tamoxifen (20 to 40 mg two times per day) with placebo in 66 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/38\">",
"     38",
"    </a>",
"    ]. Response (improvement from baseline on the mania rating scale &ge; 50 percent) occurred in significantly more patients who received tamoxifen than placebo (48 versus 5 percent), as did remission (28 versus 0 percent). Tamoxifen is widely used to prevent breast cancer because it is a selective estrogen receptor antagonist, and these antiestrogen effects preclude its use beyond patients unresponsive to most or all other treatments. &nbsp;",
"   </p>",
"   <p>",
"    There is little or no evidence to support treating acute mania or mixed episodes with anticonvulsants other than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    .",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     Lamotrigine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    are not effective for treating mania [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/46-51\">",
"     46-51",
"    </a>",
"    ]. In addition, a systematic review found that there was insufficient evidence to evaluate the anticonvulsant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/22/26982?source=see_link\">",
"     tiagabine",
"    </a>",
"    , and results from available case series are conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nor do we suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    , which has been substituted for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    to treat mania because their molecular structures are similar and oxcarbazepine has fewer side effects. There is no high quality evidence that oxcarbazepine has any benefit in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/53\">",
"     53",
"    </a>",
"    ]. In addition, a randomized trial found that oxcarbazepine was comparable with placebo in 116 manic or mixed episode children and adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H186702750\">",
"    <span class=\"h2\">",
"     Mild to moderate illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild to moderate illness is marked by the absence of suicidal or homicidal ideation or behavior, aggressiveness, psychotic features (ie, delusions or hallucinations), and poor judgement that places the patient or others at imminent risk of being harmed. Monotherapy is commonly used for initial treatment of hypomania and mild to moderate manic and mixed episodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H991964\">",
"    <span class=\"h3\">",
"     First line monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with hypomania and mild to moderate manic and mixed episodes, we suggest monotherapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    , based upon efficacy and tolerability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/51\">",
"     51",
"    </a>",
"    ]. However, reasonable alternatives include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    . Doses and side effects are discussed elsewhere in the topic. (See",
"    <a class=\"local\" href=\"#H244584\">",
"     'Medication doses and side effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A multiple-treatments meta-analysis of 68 randomized trials (16,073 patients with an acute manic or mixed episode, treated for three weeks) found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    were each significantly more efficacious than placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/51\">",
"     51",
"    </a>",
"    ]. In addition, the meta-analysis ranked these drugs by efficacy, using indirect comparisons of the drugs (through their relative effect with a common comparator, typically placebo), as well as analyzing direct comparisons between drugs. Beginning with the most efficacious drug, the rank order for efficacy was:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"       Haloperidol",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       Risperidone",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       Olanzapine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"       Aripiprazole",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       Carbamazepine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       Quetiapine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       Valproate",
"      </a>",
"      (or divalproex)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/39/4728?source=see_link\">",
"       Ziprasidone",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further, the meta-analysis ranked the drugs by frequency of treatment discontinuation for any reason, including adverse effects and lack of efficacy. Beginning with the drug with the lowest rate of dropout, the rank order was:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       Olanzapine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       Risperidone",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       Quetiapine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       Valproate",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       Carbamazepine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"       Aripiprazole",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"       Haloperidol",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/39/4728?source=see_link\">",
"       Ziprasidone",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The indirect comparisons distinguish this multiple-treatments meta-analysis from smaller, conventional meta-analyses, which concluded that efficacy was comparable for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/10,11,23,55\">",
"     10,11,23,55",
"    </a>",
"    ]. Although substantial uncertainties are introduced when these sorts of rank orders are created through a multiple-treatments meta-analysis, this is probably the best evidence for comparing drugs for acute hypomania and mild to moderate manic and mixed episodes. While it is not clear that there are meaningful differences between adjacently ranked medications, drugs near the top of the rank order are probably superior to those near the bottom of the rank order. Multiple-treatments meta-analysis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/43/39609?source=see_link&amp;anchor=H2326523#H2326523\">",
"     \"Systematic review and meta-analysis\", section on 'Network meta-analysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinicians should consider factors other than the rank order of efficacy and treatment discontinuation when choosing a drug, including the patient&rsquo;s past response to medications, the past response of family members with bipolar disorder to medications, specific symptoms, adverse drug effects, comorbid medical illnesses, concurrent medications, and cost. As an example,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    is generally avoided in patients with significant renal disease,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    in patients with liver disease, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    in obese patients. In addition,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    may be difficult to use because of its tendency to increase metabolism of concomitant medications. Medication side effects are discussed separately. (See",
"    <a class=\"local\" href=\"#H244584\">",
"     'Medication doses and side effects'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43065?source=see_link&amp;anchor=H182696807#H182696807\">",
"     \"Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects\", section on 'Lithium side effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link\">",
"     \"Pharmacology of antiepileptic drugs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/24/7562?source=see_link\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The long-term implications of choosing a drug also need to be considered; all patients with bipolar disorder should receive maintenance treatment, which commonly consists of the drug used to induce remission. As an example, maintenance",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    is common because it has been widely studied and is efficacious [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/56,57\">",
"     56,57",
"    </a>",
"    ], and long-term treatment with lithium may reduce the risk of suicide attempts and deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/58-61\">",
"     58-61",
"    </a>",
"    ]. By contrast,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    is generally not used in maintenance treatment because it can cause movement disorders and may increase the risk of bipolar major depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Maintenance treatment is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=see_link&amp;anchor=H259506193#H259506193\">",
"     \"Bipolar disorder in adults: Maintenance treatment\", section on 'Reduced risk of suicide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For mildly to moderately ill patients who do not respond to treatment with one monotherapy trial within two weeks of reaching the target dose, or do not tolerate the drug, we suggest tapering and discontinuing the failed medication over one week at the same time that another monotherapy is started and titrated up. The failed medication is generally tapered by the same amount for each dose decrease. As an example,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    600 mg per day is decreased by 100 to 200 mg per day, every one to two days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7954899\">",
"    <span class=\"h3\">",
"     Treatment resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;For hypomanic and mild to moderate manic and mixed episodes that do not respond to three to five monotherapy trials involving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    , we suggest combining lithium or valproate with an antipsychotic. However, lithium plus valproate is a reasonable alternative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Medication combinations involving lithium or valproate plus an antipsychotic are discussed elsewhere in the topic. (See",
"    <a class=\"local\" href=\"#H2269895045\">",
"     'First line medication combinations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H226715129\">",
"    <span class=\"h4\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    for patients who have hypomanic or mild to moderate manic or mixed episodes and cannot tolerate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , anticonvulsants, or antipsychotics. However,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    is a reasonable alternative. Monotherapy with a benzodiazepine is unusual due to the large number of available medication options for manic, hypomanic, or mixed episodes; benzodiazepines are generally used as adjunctive therapy to treat insomnia, agitation, or anxiety in patients with pathologic mood elevated syndromes. Given the high rate of substance use disorders among bipolar patients and the potential for abusing benzodiazepines, these drugs are generally limited to acute treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/45/26328?source=see_link\">",
"     Clonazepam",
"    </a>",
"    is usually started at a dose of 1 to 3 mg per day, taken in two divided doses. The drug is generally titrated up to a target dose ranging from 2 to 6 mg per day, depending upon efficacy and tolerability, although doses as high as 24 mg per day have been used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/67\">",
"     67",
"    </a>",
"    ]. Side effects include disinhibition, sedation, and respiratory depression.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"     Lorazepam",
"    </a>",
"    is usually started at a dose of 2 to 4 mg per day, taken in three to four divided doses. The drug is generally titrated up to a target dose ranging from 3 to 8 mg per day, depending upon efficacy and tolerability, although doses as high as 24 mg per day have been used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/67\">",
"     67",
"    </a>",
"    ]. Side effects include disinhibition, sedation, and respiratory depression.",
"   </p>",
"   <p>",
"    Evidence of efficacy includes a meta-analysis of five heterogeneous randomized trials (122 manic patients), which found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    monotherapy (2 to 24 mg per day) was efficacious [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/67\">",
"     67",
"    </a>",
"    ]. The same study analyzed four heterogeneous randomized trials (108 manic patients) involving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    (4 to 24 mg per day) and found that it was not effective. However, one randomized trial directly compared lorazepam (mean daily dose 13 mg) with clonazepam (mean daily dose 14 mg) in 24 manic patients, and found that moderate to marked improvement occurred in significantly more patients who received lorazepam than clonazepam (63 versus 18 percent), as did remission (38 versus 0 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/68\">",
"     68",
"    </a>",
"    ]. The frequency of side effects does not differ between the two drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pharmacology and abuse of benzodiazepines are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/42/24232?source=see_link\">",
"     \"Sedatives and hypnotics abuse and dependence: Pharmacology and epidemiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H244584\">",
"    <span class=\"h2\">",
"     Medication doses and side effects",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1829248939\">",
"    <span class=\"h3\">",
"     Lithium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The starting dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    is usually 300 mg two or three times daily; smaller doses (eg, 150 mg twice daily) are used in the elderly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/66,69-71\">",
"     66,69-71",
"    </a>",
"    ]. The dose should be increased by 300 to 600 mg every one to five days based upon response, tolerability, and body mass index. The goal is to reach a therapeutic serum level, which generally occurs with a dose of 900 mg to 1800 mg per day. Dose increases generally occur more frequently at the beginning of treatment, and less often as clinicians approach the target dose. Additional information about the dose of lithium is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43065?source=see_link&amp;anchor=H182696765#H182696765\">",
"     \"Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects\", section on 'Lithium dose and serum concentrations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/60/16330?source=see_link&amp;anchor=H1137967#H1137967\">",
"     \"Geriatric bipolar disorder: Acute treatment\", section on 'First line medications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The target serum level for acute treatment is between 0.8 and 1.2",
"    <span class=\"nowrap\">",
"     meq/L;",
"    </span>",
"    levels should not exceed 1.2",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    to reduce the risk of toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/70\">",
"     70",
"    </a>",
"    ]. Patients who cannot tolerate a level of 0.8",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    may respond to a level of 0.6",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    levels should be measured five to seven days after each dose increase. Levels are drawn 12 hours after the last dose (12-hour serum trough level) and generally collected in the morning, before the first dose of the day. Additional information about lithium serum levels is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43065?source=see_link&amp;anchor=H182696765#H182696765\">",
"     \"Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects\", section on 'Lithium dose and serum concentrations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    can cause many acute and long-term adverse effects. The most common acute side effects are nausea, tremor, polyuria and thirst, weight gain, loose stools, and cognitive impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. Severe or sudden worsening of acute side effects may be a sign of lithium toxicity. Over the long term, lithium can adversely affect the kidneys and thyroid gland. In addition, cardiac rhythm disturbances have been described; these almost always occur in patients with preexisting cardiac disease. Additional information about side effects and how to manage them is discussed elsewhere:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43065?source=see_link&amp;anchor=H182696807#H182696807\">",
"       \"Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects\", section on 'Lithium side effects'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/0/9225?source=see_link\">",
"       \"Lithium poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/32999?source=see_link\">",
"       \"Renal toxicity of lithium\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/29/42453?source=see_link\">",
"       \"Lithium and the thyroid\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Contraindications to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , lithium toxicity, drug interactions with lithium, the different available preparations of lithium, and laboratory tests and monitoring are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43065?source=see_link\">",
"     \"Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1829256415\">",
"    <span class=\"h3\">",
"     Anticonvulsants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticonvulsants that are efficacious for acute mania, mixed episodes, and hypomania include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52498640\">",
"    <span class=\"h4\">",
"     Suicidality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bipolar disorder is associated with an increased risk of suicide deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/74\">",
"     74",
"    </a>",
"    ], and all patients should be monitored for emergence or worsening of suicidal thoughts and behavior. Although some observational studies suggest that anticonvulsants may increase the risk of suicidal ideation or behavior, these drugs are generally safe to use when patients are regularly monitored.",
"   </p>",
"   <p>",
"    The US Food and Drug Administration warned clinicians that anticonvulsants are associated with an increased risk of suicidal thoughts and behavior, based upon a pooled analysis of 199 controlled trials that included 43,892 patients with a variety of illnesses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/75\">",
"     75",
"    </a>",
"    ]. In addition, a separate exploratory analysis of a medical and pharmacy claims database that included 297,620 new episodes of treatment with an anticonvulsant suggested that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/22/26982?source=see_link\">",
"     tiagabine",
"    </a>",
"    may be associated with an increased risk of suicidal acts or violent deaths, compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, an analysis of a different national claims database that involved 47,918 patients diagnosed specifically with bipolar disorder found [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/77\">",
"     77",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The frequency of suicide attempts did not differ significantly for patients treated with antiepileptic drugs compared with patients not receiving antiepileptic drugs",
"     </li>",
"     <li>",
"      For patients treated with antiepileptic drugs, the rate of suicide attempts was significantly higher before treatment than after treatment",
"     </li>",
"     <li>",
"      Patients receiving antiepileptic drug monotherapy (and no concomitant antidepressant or antipsychotic) had significantly fewer suicide attempts compared to patients receiving no pharmacotherapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, analyses using a national database with over 5,000,000 patients found that use of antiepileptic drugs was not associated with an increased risk of suicide attempts among patients with bipolar disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h4\">",
"     Valproate or divalproex",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     Valproate",
"    </a>",
"    is usually started at a dose of 250 mg two or three times per day. The dose is increased by 250 mg to 500 mg every one to three days as tolerated to reach a therapeutic serum level, which generally occurs with 1500 mg to 2500 mg per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/71,79\">",
"     71,79",
"    </a>",
"    ]. Valproate is usually administered twice daily (although a once-a-day formulation is available in the United States). Oral loading and rapid titration to a full dose within one to two days by prescribing 20",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    may result in earlier improvement in symptoms and a reduced need for adjunctive antipsychotics or benzodiazepines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest drawing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    serum levels two to five days after each dose increase and prescribing the drug to achieve a target serum level between 50 and 125",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    Levels should be drawn 12 hours after the last dose and generally collected in the morning, before the first dose of the day. A post hoc analysis of pooled data from three controlled trials (374 acutely manic inpatients) found that efficacy increased as serum levels increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/81\">",
"     81",
"    </a>",
"    ]. In addition, the efficacy of valproate was significantly greater than placebo for levels &ge; 71",
"    <span class=\"nowrap\">",
"     mcg/mL,",
"    </span>",
"    and the largest clinical effect for valproate occurred in patients with a mean serum level of 88",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    Levels should be checked at 6 to 12 month intervals, and are particularly useful in patients receiving medications that affect valproate concentrations and to confirm problems with adherence. Some patients may not require regular valproate levels, and one review concluded that clinical observation of efficacy and toxicity can be used to guide some dose adjustments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Common side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    include weight gain, nausea, vomiting, hair loss, easy bruising, and tremor. Divalproex is a formulation of valproate that can minimize gastrointestinal distress. Valproate is rarely associated with hepatic failure and thrombocytopenia; liver function tests and platelets should thus be monitored at 6 to 12 month intervals in all patients taking the drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/31,66,83\">",
"     31,66,83",
"    </a>",
"    ]. (The US Food and Drug Administration recommends checking liver function tests prior to initiating treatment and at frequent intervals thereafter, especially during the first six months.) In addition, valproate rarely causes pancreatitis; symptoms of abdominal pain and vomiting should prompt an assessment that includes a serum amylase and lipase.",
"   </p>",
"   <p>",
"    Additional information about the pharmacology of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    and its adverse effects and available preparations are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link&amp;anchor=H19#H19\">",
"     \"Pharmacology of antiepileptic drugs\", section on 'Valproate'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     \"Valproate: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h4\">",
"     Carbamazepine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     Carbamazepine",
"    </a>",
"    is usually started at a dose of 100 mg to 200 mg one or two times per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/71,84\">",
"     71,84",
"    </a>",
"    ]. The dose should be increased by 200 mg per day every one to four days, to a final dose of about 800 to 1000 mg per day, although the effective dose may range between 200 and 1800 mg per day. Carbamazepine is typically administered twice daily. Therapeutic serum levels have not been established for treating acute manic or mixed episodes. However, many clinicians aim for a level of 4 to 12",
"    <span class=\"nowrap\">",
"     mcg/mL,",
"    </span>",
"    which is the target range established for treating epilepsy. Extended release formulations are better tolerated in patients with bipolar disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major systemic side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    are nausea, vomiting, diarrhea, hyponatremia, rash, pruritus, leukopenia, and fluid retention. In addition, the drug is associated with life-threatening rashes (Stevens-Johnson syndrome and toxic epidermal necrolysis), particularly during the first eight weeks of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/86\">",
"     86",
"    </a>",
"    ]. This reaction is significantly more common in patients with the HLA-B*1502 allele (estimated incidence of 5 percent), which occurs almost exclusively in patients of Asian ancestry, including South Asian Indians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/87-89\">",
"     87-89",
"    </a>",
"    ]. The US Food and Drug Administration recommends screening for this allele in patients of these ethnic groups prior to starting carbamazepine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/90\">",
"     90",
"    </a>",
"    ]. Neurotoxicity includes drowsiness, dizziness, blurred or double vision, lethargy, and headache. Carbamazepine also induces liver enzymes and frequently causes drug-drug interactions that result in lower serum concentrations of concomitant drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/31,66,83\">",
"     31,66,83",
"    </a>",
"    ]. This induction of liver enzymes often decreases serum concentrations of carbamazepine. Liver function tests and a complete blood count, serum sodium, and serum carbamazepine level are recommended every 6 to 12 months.",
"   </p>",
"   <p>",
"    The pharmacology of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    and its adverse effects and available preparations are discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link&amp;anchor=H3#H3\">",
"     \"Pharmacology of antiepileptic drugs\", section on 'Carbamazepine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Antipsychotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;First- and second-generation antipsychotics are efficacious for treating both psychotic and nonpsychotic manic and mixed episodes, as well as hypomania [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/2,3,10,11,19,22,23,91\">",
"     2,3,10,11,19,22,23,91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2346270038\">",
"    <span class=\"h4\">",
"     First-generation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among first-generation antipsychotics, we prefer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    for treating manic and mixed episodes because it has been widely studied and generally causes less orthostatic hypotension and sedation than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    , which is also efficacious [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/55,92\">",
"     55,92",
"    </a>",
"    ]. Other first-generation antipsychotics such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/10/38055?source=see_link\">",
"     fluphenazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/2/27687?source=see_link\">",
"     loxapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/49/19223?source=see_link\">",
"     perphenazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/35/41526?source=see_link\">",
"     thiothixene",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/2/19495?source=see_link\">",
"     trifluoperazine",
"    </a>",
"    are effective as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest patients initially receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    at a dose of 5 to 15 mg per day, depending upon the severity of symptoms, the patient&rsquo;s body mass index, and adverse effects that emerge. The drug is taken either once per day or in two divided doses, depending upon tolerability and the patient&rsquo;s ability to adhere to treatment with divided doses. One useful guide is to prescribe 0.2 mg per kg per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/94\">",
"     94",
"    </a>",
"    ]. In a meta-analysis of 15 randomized trials (2022 patients with acute manic or mixed episodes), which found that haloperidol was comparable to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    , the dose of haloperidol ranged from 2 to 85 mg per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conventional antipsychotics are associated with extrapyramidal symptoms, akathisia, and tardive dyskinesia. Extrapyramidal symptoms are usually managed by lowering the dose of the antipsychotic or by adding an anticholinergic drug, either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/55/3958?source=see_link\">",
"     benztropine",
"    </a>",
"    1 to 2 mg two to four times daily or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/1/6165?source=see_link\">",
"     trihexyphenidyl",
"    </a>",
"    2 to 5 mg two to four times daily.",
"   </p>",
"   <p>",
"    Although switching from mania to depression has been attributed to first-generation antipsychotics, the evidence is not clear. A meta-analysis of six randomized trials (1774 manic patients; heterogeneity across studies was moderate) compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    with second-generation antipsychotics (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    ), and found that treatment emergent depression was comparable for patients who received haloperidol or second-generation antipsychotics (10 and 7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/95\">",
"     95",
"    </a>",
"    ]. However, a second analysis that excluded one outlier trial (and eliminated the heterogeneity) found that depressive switches occurred in more patients treated with haloperidol (12 versus 7 percent). In assessing patients treated with an antipsychotic, clinicians should distinguish between switching to a depressive syndrome and the side effect of affective blunting or flattening.",
"   </p>",
"   <p>",
"    The pharmacology, administration, and side effects of first-generation antipsychotics are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/24/7562?source=see_link\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20553?source=see_link\">",
"     \"Neuroleptic malignant syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/26/36264?source=see_link\">",
"     \"Tardive dyskinesia: Etiology and epidemiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2346270045\">",
"    <span class=\"h4\">",
"     Second-generation",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     Aripiprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    are each efficacious for treating manic, hypomanic, and mixed episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/51\">",
"     51",
"    </a>",
"    ], and the choice often depends upon differences in adverse side effects. Metabolic problems such as weight gain, glucose intolerance, diabetes mellitus, and hyperlipidemia are most likely to occur with olanzapine, followed by quetiapine and risperidone. Thus, patients taking olanzapine, quetiapine, and risperidone should be regularly monitored for weight, waist circumference, blood pressure, and serum glucose and lipids. Extrapyramidal side effects (EPS) are more common with aripiprazole, risperidone, or ziprasidone compared with olanzapine or quetiapine. The metabolic syndrome and EPS are discussed separately. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/45/44760?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Side effect management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The usual starting and target dose for second-generation antipsychotics and common side effects that occurred in randomized monotherapy trials are described below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/8/38026/abstract/71,96\">",
"     71,96",
"    </a>",
"    ]. Target doses can generally be achieved within one week of starting the medication. Some drugs are available as oral dissolvable formulations for patients who pretend to swallow their pills (&ldquo;cheek&rdquo;) and spit them out later when the clinician is not looking.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"       Aripiprazole",
"      </a>",
"      &ndash; Aripiprazole is started at a dose of 10 to 30 mg once daily. The usual target dose is 15 to 45 mg taken once per day. Common side effects include headache, nausea, vomiting, constipation, insomnia, and akathisia. An oral dissolvable formulation is available.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       Olanzapine",
"      </a>",
"      &ndash; Olanzapine is started at a dose of 10 to 15 mg once daily or in two divided doses. The usual target dose is 10 to 30 mg per day, taken at bedtime or in two divided doses. Some patients may require and tolerate 40 or 50 mg per day. Common side effects include sedation, constipation, dry mouth, increased appetite, weight gain, and orthostatic hypotension. An oral dissolvable formulation is available.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       Quetiapine",
"      </a>",
"      <strong>",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Quetiapine is started at a dose of 100 to 200 mg once daily or in two divided doses. The usual target dose is 400 to 800 mg taken at bedtime or in two divided doses. Some patients may require and tolerate 1000 or 1200 mg per day. Common side effects include headache, dry mouth, constipation, weight gain, sedation, dizziness, and orthostatic hypotension.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       Risperidone",
"      </a>",
"      &ndash; Risperidone is started at a dose of 1 to 2 mg once daily or in two divided doses. The usual target dose is 4 to 8 mg per day. It is usually taken in two divided doses per day, but some patients may do well with a single dose at bedtime. Common side effects include prolactin elevation, akathisia, sedation, dyspepsia, nausea, and weight gain. An oral dissolvable formulation is available.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/39/4728?source=see_link\">",
"       Ziprasidone",
"      </a>",
"      &ndash; Ziprasidone is started at a dose of 40 mg two times per day. The usual target dose is 40 to 80 mg two times per day. Some patients may require and tolerate 200 mg per day or more. Common side effects include headache, sedation, extrapyramidal symptoms, akathisia, and dizziness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional information about second-generation antipsychotics is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28431894\">",
"    <span class=\"h1\">",
"     SPECIAL CIRCUMSTANCES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28431902\">",
"    <span class=\"h2\">",
"     Elderly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of geriatric manic, hypomanic, and mixed episodes is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/60/16330?source=see_link&amp;anchor=H13749322#H13749322\">",
"     \"Geriatric bipolar disorder: Acute treatment\", section on 'Manic, hypomanic, and mixed episodes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of mania, hypomania, and mixed episodes during pregnancy; the teratogenic and postnatal risks of pharmacotherapy for bipolar disorder; the principles of teratology; preconception and prenatal maintenance pharmacotherapy for bipolar patients; and preconception counseling for patients with bipolar disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/16/4362?source=see_link\">",
"     \"Bipolar disorder in pregnant women: Treatment of mania, hypomania, and mixed episodes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11226?source=see_link\">",
"     \"Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/7/19574?source=see_link\">",
"     \"Principles of teratology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/51/2874?source=see_link\">",
"     \"Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/24/40329?source=see_link\">",
"     \"Bipolar disorder in women: Contraception and preconception assessment and counseling\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/5/4178?source=see_link\">",
"       \"Patient information: Bipolar disorder (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/55/39796?source=see_link\">",
"       \"Patient information: Bipolar disorder (manic depression) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The National Institute of Mental Health also has educational material explaining the symptoms, course of illness, and treatment in a booklet entitled \"Bipolar Disorder\" that is available online at the website",
"    <a class=\"external\" href=\"file://www.nimh.nih.gov/health/publications/bipolar-disorder/complete-index.shtml\">",
"     file://www.nimh.nih.gov/health/publications/bipolar-disorder/complete-index.shtml",
"    </a>",
"    or through a toll-free number, 866-615-6464. The web site also provides references, summaries of study results in language intended for the lay public, and information about clinical trials currently recruiting patients.",
"   </p>",
"   <p>",
"    More comprehensive information is provided in books written for patients and family members, including The Bipolar Disorder Survival Guide: What You and Your Family Need to Know, written by David J. Miklowitz, PhD (published by The Guilford Press, 2002) and An Unquiet Mind: A Memoir of Moods and Madness, written by Kay Jamison PhD (published by Random House, 1995).",
"   </p>",
"   <p>",
"    The Depression and Bipolar Support Alliance (",
"    <a class=\"external\" href=\"file://www.dbsalliance.org/\">",
"     file://www.dbsalliance.org",
"    </a>",
"    or 800-826-3632) is a national organization whose mission is to educate patients and family members about bipolar disorder and how to cope with it. Other functions include increasing public awareness of the illness and advocating for more research and services. The organization is administered and maintained by members and has local chapters.",
"   </p>",
"   <p>",
"    The National Alliance on Mental Illness (",
"    <a class=\"external\" href=\"file://www.nami.org/\">",
"     file://www.nami.org",
"    </a>",
"    or 800-950-6264) is a similarly structured organization devoted to providing education, support, and advocacy for patients with any mental illness. Bipolar disorder is one of their priorities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bipolar disorder is characterized by pathologic mood elevation. Patients with bipolar I disorder experience manic episodes (",
"      <a class=\"graphic graphic_table graphicRef81976 \" href=\"mobipreview.htm?3/53/3932\">",
"       table 1",
"      </a>",
"      ) or mixed episodes (major depression concurrent with mania or hypomania), and nearly always experience major depressive episodes (",
"      <a class=\"graphic graphic_table graphicRef70852 \" href=\"mobipreview.htm?17/21/17756\">",
"       table 3",
"      </a>",
"      ). Bipolar II disorder is characterized by at least one episode of hypomania (",
"      <a class=\"graphic graphic_table graphicRef70757 \" href=\"mobipreview.htm?22/39/23164\">",
"       table 2",
"      </a>",
"      ) and one or more episodes of major depression. (See",
"      <a class=\"local\" href=\"#H259896878\">",
"       'Definitions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=see_link&amp;anchor=H4#H4\">",
"       \"Bipolar disorder in adults: Epidemiology and diagnosis\", section on 'Clinical manifestations and diagnostic criteria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients presenting with acute mania, mixed episodes, or hypomania should be assessed for risk of suicide and homicide, aggressiveness, psychotic features, and poor judgement. Antidepressants should be discontinued, and substance abuse treated. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Drug classes commonly used to treat acute mania, mixed episodes, or hypomania include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , anticonvulsants, antipsychotics, and benzodiazepines. (See",
"      <a class=\"local\" href=\"#H259902796\">",
"       'Medication classes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with severe manic or mixed episodes, we suggest initial treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      plus an antipsychotic, rather than monotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2269895045\">",
"       'First line medication combinations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H244584\">",
"       'Medication doses and side effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For resistant patients with severe manic or mixed episodes that do not respond to one medication combination (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      plus an antipsychotic), we suggest additional medication combination trials rather than electroconvulsive therapy (ECT) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Lithium is switched to valproate (or vice versa), and the antipsychotic is switched to another antipsychotic from among",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"       aripiprazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H7956384\">",
"       'Resistant patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For treatment refractory patients with severe manic or mixed episodes who do not respond to four to six medication combinations, we suggest ECT rather than additional trials of pharmacotherapy combinations (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7956632\">",
"       'Refractory patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with acute hypomania or mild to moderate manic or mixed episodes, we suggest initial treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      monotherapy rather than other drugs (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, reasonable alternatives include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"       aripiprazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/39/4728?source=see_link\">",
"       ziprasidone",
"      </a>",
"      . In addition to efficacy and tolerability, the choice depends upon past response to medications, comorbid medical illness, concurrent medications, specific symptoms, and cost. (See",
"      <a class=\"local\" href=\"#H991964\">",
"       'First line monotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with hypomania or mild to moderate manic or mixed episodes that do not respond to three to five monotherapy trials involving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"       aripiprazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/39/4728?source=see_link\">",
"       ziprasidone",
"      </a>",
"      , we suggest combining either lithium or valproate with an antipsychotic (other than ziprasidone) rather than additional monotherapy trials (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Another option is using lithium plus valproate. (See",
"      <a class=\"local\" href=\"#H2269895045\">",
"       'First line medication combinations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/2\">",
"      American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/3\">",
"      Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005; 7 Suppl 3:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/4\">",
"      Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009; 10:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/5\">",
"      Benazzi F. Bipolar II disorder : epidemiology, diagnosis and management. CNS Drugs 2007; 21:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/6\">",
"      Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/7\">",
"      Work Group on Psychiatric Evaluation, American Psychiatric Association Steering Committee on Practice Guidlines. Psychiatric evaluation of adults. Second edition. American Psychiatric Association. Am J Psychiatry 2006; 163:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/8\">",
"      Keck PE Jr, McElroy SL, Arnold LM. Bipolar disorder. Med Clin North Am 2001; 85:645.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association Practice Guideline for the Treatment of Patients with Bipolar Disorder, Second Edition, 2002. file://www.psych.org/MainMenu/PsychiatricPractice/PracticeGuidelines_1.aspx (Accessed on August 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/10\">",
"      Smith LA, Cornelius V, Warnock A, et al. Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. Bipolar Disord 2007; 9:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/11\">",
"      Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry 2007; 64:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/12\">",
"      McElroy SL, Keck PE Jr, Pope HG Jr, et al. Clinical and research implications of the diagnosis of dysphoric or mixed mania or hypomania. Am J Psychiatry 1992; 149:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/13\">",
"      Lin D, Mok H, Yatham LN. Polytherapy in bipolar disorder. CNS Drugs 2006; 20:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/14\">",
"      Kemp DE, Johnson E, Wang WV, et al. Clinical utility of early improvement to predict response or remission in acute mania: focus on olanzapine and risperidone. J Clin Psychiatry 2011; 72:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/15\">",
"      Baldessarini RJ, Hennen J, Wilson M, et al. Olanzapine versus placebo in acute mania: treatment responses in subgroups. J Clin Psychopharmacol 2003; 23:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/16\">",
"      Swann AC, Bowden CL, Calabrese JR, et al. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. Am J Psychiatry 1999; 156:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/17\">",
"      Swann AC, Bowden CL, Morris D, et al. Depression during mania. Treatment response to lithium or divalproex. Arch Gen Psychiatry 1997; 54:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/18\">",
"      Freeman TW, Clothier JL, Pazzaglia P, et al. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry 1992; 149:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/19\">",
"      Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009; 11:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/20\">",
"      Sachs GS, Vanderburg DG, Edman S, et al. Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2012; 73:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/21\">",
"      Ketter TA. Monotherapy versus combined treatment with second-generation antipsychotics in bipolar disorder. J Clin Psychiatry 2008; 69 Suppl 5:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/22\">",
"      Smith LA, Cornelius V, Warnock A, et al. Acute bipolar mania: a systematic review and meta-analysis of co-therapy vs. monotherapy. Acta Psychiatr Scand 2007; 115:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/23\">",
"      Perlis RH, Welge JA, Vornik LA, et al. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 2006; 67:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/24\">",
"      Vieta E, T'joen C, McQuade RD, et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry 2008; 165:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/25\">",
"      Tohen M, Bowden CL, Smulevich AB, et al. Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes. Br J Psychiatry 2008; 192:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/26\">",
"      Yatham LN, Grossman F, Augustyns I, et al. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry 2003; 182:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/27\">",
"      Hilty DM, Brady KT, Hales RE. A review of bipolar disorder among adults. Psychiatr Serv 1999; 50:201.",
"     </a>",
"    </li>",
"    <li>",
"     Sachs, G. Approach to the patient with elevated, expansive, or irritable mood. In: The MGH Guide to Psychiatry in Primary Care, Stern, TA, Herman, JB, Slavin, PL (Eds), McGraw-Hill, New York 1998. p.347.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/29\">",
"      Versiani M, Cheniaux E, Landeira-Fernandez J. Efficacy and safety of electroconvulsive therapy in the treatment of bipolar disorder: a systematic review. J ECT 2011; 27:153.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association Task Force on Electroconvulsive Therapy. The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging. American Psychiatric Association, Washington, DC 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/31\">",
"      Keck PE Jr, McElroy SL, Strakowski SM. Anticonvulsants and antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 1998; 59 Suppl 6:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/32\">",
"      McIntyre RS, Cohen M, Zhao J, et al. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord 2010; 122:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/33\">",
"      McIntyre RS, Cohen M, Zhao J, et al. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord 2009; 11:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/34\">",
"      Calabrese JR, Kimmel SE, Woyshville MJ, et al. Clozapine for treatment-refractory mania. Am J Psychiatry 1996; 153:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/35\">",
"      Green AI, Tohen M, Patel JK, et al. Clozapine in the treatment of refractory psychotic mania. Am J Psychiatry 2000; 157:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/36\">",
"      Vieta E, Nuamah IF, Lim P, et al. A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disord 2010; 12:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/37\">",
"      Machado-Vieira R, Soares JC, Lara DR, et al. A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. J Clin Psychiatry 2008; 69:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/38\">",
"      Yildiz A, Guleryuz S, Ankerst DP, et al. Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry 2008; 65:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/39\">",
"      Kulkarni J, Garland KA, Scaffidi A, et al. A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology 2006; 31:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/40\">",
"      Zarate CA Jr, Singh JB, Carlson PJ, et al. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord 2007; 9:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/41\">",
"      Amrollahi Z, Rezaei F, Salehi B, et al. Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania. J Affect Disord 2011; 129:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/42\">",
"      Berwaerts J, Xu H, Nuamah I, et al. Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: a randomized, double-blind, dose-response study. J Affect Disord 2012; 136:e51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/43\">",
"      Berwaerts J, Lane R, Nuamah IF, et al. Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study. J Affect Disord 2011; 129:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/44\">",
"      Fan A, Berg A, Bresee C, et al. Allopurinol augmentation in the outpatient treatment of bipolar mania: a pilot study. Bipolar Disord 2012; 14:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/45\">",
"      Anumonye A, Reading HW, Knight F, Ashcroft GW. Uric-acid metabolism in manic-depressive illness and during lithium therapy. Lancet 1968; 1:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/46\">",
"      Dunn RT, Frye MS, Kimbrell TA, et al. The efficacy and use of anticonvulsants in mood disorders. Clin Neuropharmacol 1998; 21:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/47\">",
"      Vasudev K, Macritchie K, Geddes J, et al. Topiramate for acute affective episodes in bipolar disorder. Cochrane Database Syst Rev 2006; :CD003384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/48\">",
"      Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/49\">",
"      Roy Chengappa KN, Schwarzman LK, Hulihan JF, et al. Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: a randomized, placebo-controlled trial. J Clin Psychiatry 2006; 67:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/50\">",
"      Yatham LN. Newer anticonvulsants in the treatment of bipolar disorder. J Clin Psychiatry 2004; 65 Suppl 10:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/51\">",
"      Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 2011; 378:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/52\">",
"      Young AH, Geddes JR, Macritchie K, et al. Tiagabine in the treatment of acute affective episodes in bipolar disorder: efficacy and acceptability. Cochrane Database Syst Rev 2006; :CD004694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/53\">",
"      Vasudev A, Macritchie K, Vasudev K, et al. Oxcarbazepine for acute affective episodes in bipolar disorder. Cochrane Database Syst Rev 2011; :CD004857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/54\">",
"      Wagner KD, Kowatch RA, Emslie GJ, et al. A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry 2006; 163:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/55\">",
"      Cipriani A, Rendell JM, Geddes JR. Haloperidol alone or in combination for acute mania. Cochrane Database Syst Rev 2006; :CD004362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/56\">",
"      BALANCE investigators and collaborators, Geddes JR, Goodwin GM, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010; 375:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/57\">",
"      Smith LA, Cornelius V, Warnock A, et al. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord 2007; 9:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/58\">",
"      Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005; 162:1805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/59\">",
"      Baldessarini RJ, Tondo L, Hennen J. Treating the suicidal patient with bipolar disorder. Reducing suicide risk with lithium. Ann N Y Acad Sci 2001; 932:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/60\">",
"      Kessing LV, S&oslash;nderg&aring;rd L, Kvist K, Andersen PK. Suicide risk in patients treated with lithium. Arch Gen Psychiatry 2005; 62:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/61\">",
"      Goodwin FK, Fireman B, Simon GE, et al. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003; 290:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/62\">",
"      Keck PE Jr, McElroy SL, Strakowski SM, Soutullo CA. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. J Clin Psychiatry 2000; 61 Suppl 4:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/63\">",
"      Keck PE Jr, McElroy SL, Strakowski SM. Schizoaffective disorder: role of atypical antipsychotics. Schizophr Res 1999; 35 Suppl:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/64\">",
"      Maina G, Albert U, Salvi V, et al. Valproate or olanzapine add-on to lithium: an 8-week, randomized, open-label study in Italian patients with a manic relapse. J Affect Disord 2007; 99:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/65\">",
"      Reischies FM, Hartikainen J, Bergh&ouml;fer A. Initial lithium and valproate combination therapy in acute mania. Neuropsychobiology 2002; 46 Suppl 1:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/66\">",
"      Griswold KS, Pessar LF. Management of bipolar disorder. Am Fam Physician 2000; 62:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/67\">",
"      Curtin F, Schulz P. Clonazepam and lorazepam in acute mania: a Bayesian meta-analysis. J Affect Disord 2004; 78:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/68\">",
"      Bradwejn J, Shriqui C, Koszycki D, Meterissian G. Double-blind comparison of the effects of clonazepam and lorazepam in acute mania. J Clin Psychopharmacol 1990; 10:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/69\">",
"      Glick ID, Suppes T, DeBattista C, et al. Psychopharmacologic treatment strategies for depression, bipolar disorder, and schizophrenia. Ann Intern Med 2001; 134:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/70\">",
"      Drugs for psychiatric disorders. Treat Guidel Med Lett 2006; 4:35.",
"     </a>",
"    </li>",
"    <li>",
"     Labbate, LA, Fava, M, Rosenbaum, JF, et al. Drugs for treatment of bipolar disorders. In: Handbook of Psychiatric Drug Therapy, 6th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2010. p.110.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/72\">",
"      Freeman MP, Freeman SA. Lithium: clinical considerations in internal medicine. Am J Med 2006; 119:478.",
"     </a>",
"    </li>",
"    <li>",
"     Freeman, MP, Wiegand, et al. Lithium. In: The American Psychiatric Publishing Textbook of Psychopharmacology, 4th, Schatzberg, AF, Nemeroff, CB (Eds), American Psychiatric Publishing, Inc, Washington, D.C. 2009. p.697.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/74\">",
"      Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 2002; 68:167.",
"     </a>",
"    </li>",
"    <li>",
"     Information for healthcare professionals: suicidal behavior and ideation and antiepileptics drugs. Published January 31, 2008. Updated December 16, 2008. file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm100192.htm (Accessed on December 10, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/76\">",
"      Patorno E, Bohn RL, Wahl PM, et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA 2010; 303:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/77\">",
"      Gibbons RD, Hur K, Brown CH, Mann JJ. Relationship between antiepileptic drugs and suicide attempts in patients with bipolar disorder. Arch Gen Psychiatry 2009; 66:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/78\">",
"      Arana A, Wentworth CE, Ayuso-Mateos JL, Arellano FM. Suicide-related events in patients treated with antiepileptic drugs. N Engl J Med 2010; 363:542.",
"     </a>",
"    </li>",
"    <li>",
"     Bowden, CL. Valproate. In: The American Psychiatric Publishing Textbook of Psychopharmacology, 4th, Schatzberg, AF, Nemeroff, CB (Eds), American Psychiatric Publishing, Inc., Washington, D.C. 2009. p.719.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/80\">",
"      Keck PE Jr, McElroy SL, Tugrul KC, Bennett JA. Valproate oral loading in the treatment of acute mania. J Clin Psychiatry 1993; 54:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/81\">",
"      Allen MH, Hirschfeld RM, Wozniak PJ, et al. Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am J Psychiatry 2006; 163:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/82\">",
"      Haymond J, Ensom MH. Does valproic acid warrant therapeutic drug monitoring in bipolar affective disorder? Ther Drug Monit 2010; 32:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/83\">",
"      Sachs GS, Thase ME. Bipolar disorder therapeutics: maintenance treatment. Biol Psychiatry 2000; 48:573.",
"     </a>",
"    </li>",
"    <li>",
"     Ketter TA, Wang PW, Post RM. Carbamazepine and oxcarbazepine. In: The American Psychiatric Publishing Textbook of Psychopharmacology, 4th, Schatzberg, AF, Nemeroff, CB (Eds), American Psychiatric Publishing, Inc., Washington, D.C. 2009. p.735.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/85\">",
"      El-Mallakh RS, Salem MR, Chopra AS, et al. Adverse event load in bipolar participants receiving either carbamazepine immediate-release or extended-release capsules: a blinded, randomized study. Int Clin Psychopharmacol 2009; 24:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/86\">",
"      Rzany B, Correia O, Kelly JP, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 1999; 353:2190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/87\">",
"      Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/88\">",
"      Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006; 16:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/89\">",
"      Man CB, Kwan P, Baum L, et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007; 48:1015.",
"     </a>",
"    </li>",
"    <li>",
"     Information for Healthcare Professionals: Dangerous or Even Fatal Skin Reactions - Carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics)",
" file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124718.htm (Accessed on October 05, 2010).",
"    </li>",
"    <li>",
"     Hirschfeld, RM. Guideline Watch: Practice guideline for the treatment of patients with bipolar disorder. Arlington, VA; American Psychiatric Association www.psych.org/psych_pract/treatg/pg/prac_guide.cfm (Accessed on May 11, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/92\">",
"      Prien RF, Caffey EM Jr, Klett CJ. Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group. Arch Gen Psychiatry 1972; 26:146.",
"     </a>",
"    </li>",
"    <li>",
"     Medical treatment of hypomania, mania, and mixed states. In: Manic-Depressive Illness:Bipolar Disorders and Recurrent Depression, 2nd, Goodwin, FK, Jamison, KR (Eds), Oxford University Press, Oxford 2007. p.736.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/94\">",
"      McElroy SL, Keck PE, Stanton SP, et al. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry 1996; 57:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/8/38026/abstract/95\">",
"      Goikolea JM, Colom F, Torres I, et al. Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol. J Affect Disord 2013; 144:191.",
"     </a>",
"    </li>",
"    <li>",
"     Keck, PE, McElroy, SL. Treatment of bipolar disorder. In: The American Psychiatric Publishing Textbook of Psychopharmacology , 4th, Schatzberg, AF, Nemeroff, CB (Eds), American Psychiatric Publishing, Inc., Washington, D.C. 2009. p.1113.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 679 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.131.41.98-0FBBA5EC0B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_8_38026=[""].join("\n");
var outline_f37_8_38026=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H259896878\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H324798\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H324989\">",
"      Goal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H226715056\">",
"      - Setting and monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H259902796\">",
"      - Medication classes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H259901057\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H259901050\">",
"      - Predictors of response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7954915\">",
"      Severe manic and mixed episodes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2269895045\">",
"      - First line medication combinations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7956384\">",
"      - Resistant patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7956632\">",
"      - Refractory patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7956662\">",
"      Electroconvulsive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H326320\">",
"      Other medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H186702750\">",
"      Mild to moderate illness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H991964\">",
"      - First line monotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7954899\">",
"      - Treatment resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H226715129\">",
"      Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H244584\">",
"      Medication doses and side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1829248939\">",
"      - Lithium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1829256415\">",
"      - Anticonvulsants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H52498640\">",
"      Suicidality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Valproate or divalproex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Carbamazepine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2346270038\">",
"      First-generation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2346270045\">",
"      Second-generation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28431894\">",
"      SPECIAL CIRCUMSTANCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28431902\">",
"      Elderly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/679\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/679|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/53/3932\" title=\"table 1\">",
"      DSM-IV-TR diagnostic criteria for mania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/39/23164\" title=\"table 2\">",
"      DSM-IV-TR diagnostic criteria for hypomania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/21/17756\" title=\"table 3\">",
"      DSM-IV-TR diagnostic criteria for major depression",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/22/25962?source=related_link\">",
"      Assessment and management of the acutely agitated or violent adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43065?source=related_link\">",
"      Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=related_link\">",
"      Bipolar disorder in adults: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=related_link\">",
"      Bipolar disorder in adults: Maintenance treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44088?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11226?source=related_link\">",
"      Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/16/4362?source=related_link\">",
"      Bipolar disorder in pregnant women: Treatment of mania, hypomania, and mixed episodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/24/40329?source=related_link\">",
"      Bipolar disorder in women: Contraception and preconception assessment and counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/51/2874?source=related_link\">",
"      Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/24/7562?source=related_link\">",
"      First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/60/16330?source=related_link\">",
"      Geriatric bipolar disorder: Acute treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/29/42453?source=related_link\">",
"      Lithium and the thyroid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/0/9225?source=related_link\">",
"      Lithium poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21145?source=related_link\">",
"      Medical consultation for electroconvulsive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20553?source=related_link\">",
"      Neuroleptic malignant syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/21/41305?source=related_link\">",
"      Overview of electroconvulsive therapy (ECT) for adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/5/4178?source=related_link\">",
"      Patient information: Bipolar disorder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/55/39796?source=related_link\">",
"      Patient information: Bipolar disorder (manic depression) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/38/2665?source=related_link\">",
"      Pharmacotherapy for generalized anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/45/44760?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Side effect management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/7/19574?source=related_link\">",
"      Principles of teratology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/32999?source=related_link\">",
"      Renal toxicity of lithium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/42/24232?source=related_link\">",
"      Sedatives and hypnotics abuse and dependence: Pharmacology and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/43/39609?source=related_link\">",
"      Systematic review and meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/26/36264?source=related_link\">",
"      Tardive dyskinesia: Etiology and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13128?source=related_link\">",
"      Technique for performing electroconvulsive therapy (ECT) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/62/13290?source=related_link\">",
"      Treatment of insomnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=related_link\">",
"      Valproate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_8_38027="Causes of Eisenmenger syndrome";
var content_f37_8_38027=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of Eisenmenger syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Atrial shunts*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Atrial septal defects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Primum, secundum, sinus venosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Common atrium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total anomalous pulmonary venous connection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Partial anomalous pulmonary venous connection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Ventricular shunts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ventricular septal defect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Single ventricle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transposition of the great vessels with VSD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Double outlet right ventricle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atrioventricular canal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Aortic shunts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patent ductus arteriosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aortopulmonary window (defect)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Truncus arteriosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonic valve atresia with VSD and large collateral vessels",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     *&nbsp;There is controversy regarding the role of atrial septal defects (ASDs) in the development of Eisenmenger syndrome. Some experts believe that pulmonary hypertension in patients with secundum ASDs (which occurs in less than 10 percent) is due to the coincidental occurrence of primary pulmonary hypertension in these patients.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_8_38027=[""].join("\n");
var outline_f37_8_38027=null;
var title_f37_8_38028="Prog brain mets HER2-pos BC";
var content_f37_8_38028=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F80803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F80803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prognosis of patients with brain metastases from HER2-positive breast cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Study",
"       </td>",
"       <td class=\"subtitle1\">",
"        Time period",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of patients",
"       </td>",
"       <td class=\"subtitle1\">",
"        Median survival after CNS recurrence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tham, et al",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        1970-1999",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        ~3 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bendell, et al",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td>",
"        1998-2000",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        13 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gori, et al",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td>",
"        1999-2005",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        23 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stemmler, et al",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td>",
"        2000-2004",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        13 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eichler, et al",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"       <td>",
"        2001-2005",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        17 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Melisko, et al",
"        <sup>",
"         [6]",
"        </sup>",
"       </td>",
"       <td>",
"        1997-2007",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        23 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brufsky, et al",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"       <td>",
"        2003-2009",
"       </td>",
"       <td>",
"        377",
"       </td>",
"       <td>",
"        20.3 months",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Trastuzumab approved by the United States Food and Drug Administration (FDA) for treatment of HER2-positive, metastatic breast cancer in 1998.",
"    <div class=\"footnotes\">",
"     CNS: central nervous system; HER2: human epidermal growth factor receptor 2.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Tham YL, Sexton K, Kramer R, et al. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 2006; 107:696.",
"       </li>",
"       <li>",
"        Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003; 97:2972.",
"       </li>",
"       <li>",
"        Gori S, Rimondini S, De Angelis V, et al. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. Oncologist 2007; 12:766.",
"       </li>",
"       <li>",
"        Stemmler HJ, Kahlert S, Siekiera W, et al. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 2006; 15:219.",
"       </li>",
"       <li>",
"        Eichler AF, Kuter I, Ryan P, et al. Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer 2008; 112:2359.",
"       </li>",
"       <li>",
"        Melisko ME, Moore DH, Sneed PK, et al. Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival. J Neurooncol 2008; 88:359.",
"       </li>",
"       <li>",
"        Brufsky AM, Mayer M, Rugo HS, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res 2011; 17:4834.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_8_38028=[""].join("\n");
var outline_f37_8_38028=null;
var title_f37_8_38029="Pulmonary vein velocity schematic";
var content_f37_8_38029=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schematic of normal pulmonary venous flow velocity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 403px; height: 342px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pulmonary venous velocity time integrals in systole (VTIs) and diastole (VTId) are determined by planimetry. The VTIs consists of two peaks due to early and late systolic atrial filling; the VTId contains a short pulmonary venous flow reversal after atrial contraction. A predominantly negative VTIs (VTIs &lt;0) translates into VTIs/VTId &lt;0, compatible with significant mitral regurgitation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Seiler C, Aeschbacher BC, Meier B. J Am Coll Cardiol 1998; 31:1383.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_8_38029=[""].join("\n");
var outline_f37_8_38029=null;
var title_f37_8_38030="Uterus didelphys bicollis";
var content_f37_8_38030=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uterus didelphys, bicollis, with complete upper vaginal septum with bilateral obstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 284px; height: 208px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_8_38030=[""].join("\n");
var outline_f37_8_38030=null;
var title_f37_8_38031="Xanthogranulomatous PN gross";
var content_f37_8_38031=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F80578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F80578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Xanthogranulomatous PN gross",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 196px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gross specimen of a kidney with a segmental area of xanthogranulomatous pyelonephritis (arrow) surrounding a calcium stone (S). The yellow tissue in this area represents an inflammatory reaction with lipid-filled macrophages.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_8_38031=[""].join("\n");
var outline_f37_8_38031=null;
    